Kentucky’s
COVID-19 Vaccination Plan

 UPDATED FEBRUARY 8TH 2021

Version 2
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreward</td>
<td>2</td>
</tr>
<tr>
<td>Section 1: Preparedness Planning</td>
<td>3</td>
</tr>
<tr>
<td>Section 2: COVID-19 Organizational Structure</td>
<td>6</td>
</tr>
<tr>
<td>Section 3: Vaccination Planning Phases</td>
<td>8</td>
</tr>
<tr>
<td>Section 4: Critical Populations</td>
<td>11</td>
</tr>
<tr>
<td>Section 5: Vaccination Provider Recruitment and enrollment</td>
<td>18</td>
</tr>
<tr>
<td>Section 6: Vaccine Administration Capacity</td>
<td>20</td>
</tr>
<tr>
<td>Section 7: Vaccine Allocation, Ordering, Distribution, and inventory management</td>
<td>24</td>
</tr>
<tr>
<td>Section 8: Vaccine Storage &amp; Handling</td>
<td>30</td>
</tr>
<tr>
<td>Section 9: Vaccine Administration, documentation and reporting</td>
<td>33</td>
</tr>
<tr>
<td>Section 10: Vaccine Second Dose reminders</td>
<td>37</td>
</tr>
<tr>
<td>Section 11: Immunization information systems</td>
<td>38</td>
</tr>
<tr>
<td>Section 12: vaccination communication</td>
<td>41</td>
</tr>
<tr>
<td>Section 13: Regulatory Considerations</td>
<td>44</td>
</tr>
<tr>
<td>Section 14: Vaccine safety and monitoring</td>
<td>46</td>
</tr>
<tr>
<td>Section 15: vaccination program monitoring</td>
<td>47</td>
</tr>
<tr>
<td>Organization and Assignment of Responsibilities</td>
<td>48</td>
</tr>
<tr>
<td>Authorities and References</td>
<td>53</td>
</tr>
<tr>
<td>Attachment 1: Vaccination Resources and Checklists</td>
<td>54</td>
</tr>
<tr>
<td>attachment 2: Overview of Allocation Frameworks</td>
<td>56</td>
</tr>
<tr>
<td>Attachment 3: Framework for Equitable Allocation of COVID-19 Vaccine</td>
<td>57</td>
</tr>
<tr>
<td>Attachment 4: Projected vaccination Target Groups</td>
<td>59</td>
</tr>
<tr>
<td>Attachment 5: Vaccine “A” Information</td>
<td>62</td>
</tr>
<tr>
<td>Attachment 6: Vaccine “B” Information</td>
<td>65</td>
</tr>
<tr>
<td>Attachment 7: Kentucky’s Interim Recommendation for</td>
<td>66</td>
</tr>
<tr>
<td>Allocating Supplies of COVID-19 Vaccine</td>
<td>66</td>
</tr>
</tbody>
</table>
FOREWARD

SARS-CoV-2, the virus that causes COVID-19, first appeared in Wuhan, China in December 2019. Since that time, it has spread to many countries and was declared a pandemic on March 11, 2020 by the World Health Organization (WHO). In order to limit the spread of COVID-19, many countries, including the United States, implemented enhanced disease surveillance and control measures such as stay at home orders to encourage physical distancing, requiring the use of facial coverings, and promoting increased hand hygiene.

Immunization with a safe and effective vaccine is another critical component of containing and limiting the spread of COVID-19 related illnesses. The United States has established a goal to have enough vaccine for all people in the United States who wish to be vaccinated. The Kentucky Department for Public Health (KDPH) is developing a plan on achieving this goal for all Kentuckians.

This is the second draft version of Kentucky’s COVID-19 Vaccination Plan (Version 2.0), which builds upon draft Version 1 and incorporates the assumptions, guidance, and requirements in the Centers for Disease Control and Prevention (CDC) COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations, issued on September 16, 2020. As additional information and guidance are available, the plan will evolve and be updated to meet the needs of all Kentuckians. Planning activities are ongoing as the timelines and planning assumptions from Operation Warp Speed continue to evolve.
SECTION 1: PREPAREDNESS PLANNING

Introduction
Since the 1970s, responding to infectious disease pandemics — predominantly those caused by the influenza virus — has been a recurring activity in the United States. As part of these efforts, both states and the federal government have planned for mass distribution of vaccines and other pharmaceuticals long before the advent of COVID-19. On an annual basis, a unique seasonal influenza (flu) vaccine is manufactured and distributed for public consumption. As recently as 2009-2010, the H1N1 influenza virus resulted in a global pandemic necessitating the development and distribution of unique vaccines at a national scale. These prior experiences along with others for unrelated threats such as anthrax requiring medical countermeasure distribution plans provide substantial knowledge and experience to inform the Kentucky Department for Public Health’s (KDPH) COVID-19 vaccine strategy.

On May 15, 2020, the Trump administration announced Operation Warp Speed (OWS) which aims to “deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.” OWS includes major federal support for the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. Once a vaccine is developed, the federal government is likely to procure all available product and centralize distribution to states. The algorithms for allocation are unknown at this time, but current recommendations for vaccination apportionment suggests that it be done in proportion to state populations, as occurred during the 2009 influenza pandemic.

Vaccine deployment is a multi-agency effort. The U.S. Department for Health and Human Services (HHS) is the lead agency for the federal COVID-19 response. Playing substantial support roles, the U.S. Department of Defense (DOD) has been assisting with distribution and administration of the vaccine, while the Defense Logistics Agency (DLA) is providing contract, logistics, and administrative support to the distribution process.

On July 30th, the CDC held a meeting with immunization stakeholders and outlined a general framework for distribution. The announcement alludes to a distribution model similar to that used for H1N1 vaccine: industry will deliver vaccine to a central distributor from which supply states and territories will receive weekly allocations. Vaccine administration sites — including private providers, clinics, government-run points of dispensing (POD), and others — will submit requests to the states who will prioritize and approve those requests against their daily allotment. Once a request has been approved by the state, the distribution will be made directly from the central distributor to the receiving site via contracts arranged by the DLA. Additional direct allocations will be made to select private partners (including major retail pharmacies, names TBA) to expand access.

When a vaccine is authorized for use, its supply is usually limited due to finite manufacturing capacity, the slower speed of some technologies, and the logistical challenges of distribution and administration of the vaccine. Distribution and logistics issues also have implications for other vaccines that may contribute to improved health status. Therefore, the entire vaccine distribution system should be considered.

KDPH is considering the short, medium and long-term actions necessary to lay the foundation for a smooth and orderly COVID-19 vaccination campaign. Concurrently, electronic health record vendors and immunization information systems (IIS) are updating and preparing these data reporting systems.
accordingly with consideration given to target populations and phases of vaccine distribution across the health care system, critical population groups, and the general public.

**Purpose**

Kentucky’s Vaccination Plan outlines the actions, roles, and responsibilities of state agencies and collaborating organizations that are necessary for a smooth and orderly COVID-19 vaccination distribution and administration process. This plan primarily covers those “critical” activities that have been identified for a successful COVID-19 vaccination campaign. Adjunct objectives and tasks may be added during operations to cover situations that arise or that are not addressed in this plan.

**Scope**

Kentucky’s Vaccination Plan is applicable to Kentucky’s COVID-19 vaccination campaign and will be used in conjunction with the Kentucky Emergency Operations Plan (EOP), the Emergency Support Function (ESF) #8 – Public Health and Medical Services Annex, the Kentucky Medical Countermeasures (MCM) Plan, the Kentucky Disease Outbreak Support Plan (DOSP), and other relevant plans as listed in the Authorities and References section.

**Objectives**

- Ensure timely and equitable distribution of vaccine;
- Provide all Kentuckians the opportunity to receive the COVID-19 vaccine;
- Track vaccine use across the state;
- Monitor vaccine safety; and
- Ensure access to accurate and timely information on vaccine use and availability.

**Planning Assumptions**

Planning assumptions are events, or circumstances that are expected to occur during an incident and affect the operational environment of the response. The following assumptions have been made in the development of this plan:

a. The efficacy of additional vaccines that may be approved/authorized is uncertain at present and will not be known with certainty for some time.

b. Vaccine will be free of cost, but administration fees may not be reimbursable while a vaccine product is administered under an Emergency Use Authorization (EUA).

c. More than one vaccine will be available at the same time. These vaccines may have different safety and efficacy profiles across different population groups and may have different logistical requirements.

d. Limited COVID-19 vaccine doses may be available in late 2020, but COVID-19 vaccine supply will increase substantially in 2021.

e. Initially available COVID-19 vaccines will either be approved as licensed vaccines or authorized for use under an Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA).

f. Cold chain storage and handling requirements for each COVID-19 vaccine product will vary from refrigerated (2°C to 8°C) to frozen (-20°C) to ultra-cold (-60°C to -80°C) temperatures, and
ongoing stability testing may impact these requirements. Note: Updated information will be provided as it becomes available.

g. As with other new medical treatments, post-marketing surveillance will be necessary to more fully define the long-term safety profile of approved vaccines.

h. KDPH will receive a vaccine allocation based on Kentucky's proportion of the U.S. population.

i. Some of the candidate vaccines will require two doses to produce protective immunity.

j. The number of healthcare personnel qualified to dispense or administer the vaccines and the number of volunteers available to perform support functions will limit the rate at which the vaccines can be dispensed.

k. It may take many months before most U.S. residents have access to vaccination; bottlenecks at various stages of the vaccine manufacturing process (e.g., supply of vials or syringes, fill and finish process) could cause further delays in vaccine availability.

l. Specialized vaccine distribution systems and outreach efforts to provide access to some of the highest-risk populations may be needed.

m. Access to sufficient personal protective equipment (PPE) may be a limitation once wide scale vaccination operations take place.

n. The vaccine will be distributed and administered via multiple pathways such as hospitals, medical offices, clinics, local health departments, pharmacies, and other locations.

o. A portion of the U.S. population is hesitant to receive a COVID-19 vaccine.

p. The CDC will provide ancillary vaccination supplies such as needles, syringes, alcohol swabs, etc.

q. Prioritization decisions will occur in stages as supply increases.

r. Guidance from the CDC and the Advisory Committee on Immunization Practices (ACIP) will change, likely over a relatively short time (weeks and months). KDPH will take this guidance into consideration when determining phases and distribution of the vaccine.

s. There will be times when supply is insufficient even for the most vulnerable populations, and KDPH will need to carefully consider how to distribute the limited supply.

t. Prioritization will be based on a combination of job functions, exposure potential (i.e., hospital patient care workers, EMS, nursing homes), and individual risk factors for severe illness or poor outcomes.

u. Provider participation in administering the vaccine is voluntary.

v. Individuals are not required by the state to receive the vaccine.
SECTION 2: COVID-19 ORGANIZATIONAL STRUCTURE

Planning and Coordination Team

Kentucky’s vaccination planning is a combined state and local responsibility that requires close collaboration between KDPH, Local Health Departments (LHDs) external agencies, and community partners. Kentucky public health has a “shared governance” health structure within which both KDPH and LHDs will play a key role ensuring a successful COVID-19 vaccination campaign.

In May of 2020, KDPH stood up a COVID-19 Vaccination Planning Team. The current COVID-19 Vaccination Planning Team structure follows the structure set forth in the Incident Command System (ICS) and is a “Branch” under KDPH’s COVID-19 ICS structure. The COVID-19 Vaccination Planning Team has a wide array of expertise and representation. Some team members represent partners (e.g. Fire, EMS, and Law Enforcement) and will serve as conduits for communication and planning assistance. Many of the team members involved in planning will also be involved in the execution and implementation of the vaccination plan.

Vaccine Distribution Advisory Committee

Reaching intended vaccine recipients is essential to achieving desired levels of COVID-19 vaccination coverage. To ensure equitable access to vaccinations, information about populations within a jurisdiction and the logistical requirements for providing them access to COVID-19 vaccination services requires collaboration with external entities and community partners. To facilitate equitable access, KDPH established a COVID-19 Vaccination Allocation Advisory Committee (VAAC). KDPH is utilizing the Kentucky Health and Medical Preparedness Committee (HMPAC), as well as leadership from KDPH’s COVID-19
planning and coordination team and representatives for critical population groups identified by CDC. In 2011, the CDC Public Health Emergency Preparedness (PHEP) Cooperative Agreement required funding recipients to establish and maintain an advisory committee(s) comprised of senior officials from governmental and nongovernmental partners to integrate preparedness efforts across jurisdictions. It is advantageous for KDPH to utilize the HMPAC because membership includes senior representatives from multiple disciplines and partner organizations as well as community-based partners representing at-risk populations (individuals with disabilities and others with access and functional needs). The VAAC, an ad hoc committee of the HMPAC consists of applicable HMPAC members and KDPH leadership. The VAAC reviews and discusses the “CDC’s suggested COVID-19 vaccine targeting guidance” in which they advise whether the vaccine targeting guidance should be used or if it should be modified and how, based upon Kentucky’s unique circumstances. The VAAC’s recommendations are then reviewed by the Governor and the Public Health Commissioner for final endorsement or adjustment. Further details are explained in “Section 4: Critical Populations.”

**Operational Coordination Structure**

KDPH utilizes the Kentucky Emergency Operations Plan (EOP), the ESF #8 – Public Health and Medical Services Annex, the State Health Operations Center (SHOC) Support Plan and the Kentucky Medical Countermeasures Distribution Plan to guide and coordinate vaccine distribution. The aforementioned plans contain detailed information on how incidents are managed and coordinated. KDPH uses these plans to coordinate, support, and/or manage vaccine operations.

The SHOC serves as the base of direction, control, and coordination for Kentucky’s COVID-19 vaccination campaign. The SHOC works in coordination with the State Emergency Operations Center (SEOC). The agencies and organizations identified within this plan ensures the necessary personnel and resources are available to achieve the operational objectives. It is expected that personnel from supporting agencies will operate in accordance with the rules, regulations, and capabilities of their respective agency or organization and that local governments are responsible under all applicable laws, executive orders, proclamations, rules, regulations, and ordinances for vaccination operations and response within their respective jurisdiction(s).

KDPH is utilizing the following systems to share information and manage the COVID-19 vaccination campaign (where applicable):

- Kentucky Immunization Registry (KYIR)
- Vaccine Adverse Events Reporting System (VAERS)
- Vaccine Tracking System (VTrckS)
- Tiberius
- ReadyOp
- WebEOC
- Email
SECTION 3: VACCINATION PLANNING PHASES

Due to changing vaccine supply levels at various points during the COVID-19 Vaccination Program, planning should be flexible but as specific as possible to accommodate a variety of scenarios. Vaccine supply is limited at the beginning, so in the allocation of doses, KDPH must consider vaccination providers and settings for vaccination of limited critical populations. The vaccine supply is projected to increase quickly, however, allowing vaccination efforts to be expanded to include additional critical populations and the general public. Additionally, recommendations on the various population groups targeted for initial doses of vaccine could change as more vaccine is available, depending on each vaccine’s characteristics, vaccine supply, disease epidemiology, and local community factors. Populations of focus for initial COVID-19 vaccination are:

- Healthcare personnel in clinical settings (inpatient, outpatient, dental, home-based)
- Long-term care facility/ALF staff and residents
- First Responders likely to be exposed to or treat people with COVID-19;
- K-12 school personnel
- Individuals 70 years of age and older

The CDC outlines the following phases for jurisdictions to consider in planning:

**Phase 1a to 1b: Limited supply of COVID-19 vaccine doses available**

Focus initial efforts on reaching the critical populations listed above. Ensure vaccination locations selected can reach populations, manage cold chain requirements, and meet reporting requirements for vaccine supply and uptake.

In Phase 1, initial doses of vaccine are distributed in a limited manner with the goals of maximizing vaccine acceptance and public health protection while minimizing waste and inefficiency. The key considerations in planning for this phase are:

- COVID-19 vaccine supply will be limited;
- COVID-19 vaccine administration efforts must concentrate on targeted populations to achieve vaccination coverage in those groups; and
- Inventory, distribution, and any repositioning of vaccine will be closely monitored through reporting to ensure end-to-end visibility of vaccine doses.

Enrollment activities will be prioritized for vaccination providers and settings who will administer COVID-19 vaccine to Phase 1 targeted populations.

**Phase 1c to Phase 2: Likely larger number of vaccine doses available; Expanded vaccination capability**

Focus on ensuring access to vaccine for members of Phase 1 critical populations not yet vaccinated, extend efforts to reach the general population, and expand the vaccine provider network. Phase 2 will likely include the need for additional vaccinators to staff PODs (i.e., points of distribution), contract for vaccination services, and expand professional scopes of practice (if necessary). As the supply of available vaccine increases, distribution will expand to increase access to vaccination services to a larger population. When larger quantities of vaccine become available, we plan to conduct two simultaneous objectives:

- Provide equitable access to COVID-19 vaccination for target groups; and
• Provide equitable access to COVID-19 vaccination for critical populations.

As the supply of available vaccine increases, access to vaccination services will expand for a larger population. Key considerations in Phase 1c to Phase 2 will be:

• COVID-19 vaccine supply will likely be sufficient to meet demand for critical populations as well as the general public;
• Additional COVID-19 vaccine doses available will permit an increase in vaccination providers and locations;
• A surge in COVID-19 vaccine demand is possible, so a broad vaccine administration network for surge capacity will be necessary; and
• Low COVID-19 vaccine demand is also a possibility, so jurisdictions should monitor supply and adjust strategies to minimize vaccine wastage.

Phase 3: Likely sufficient supply of vaccine doses to meet demand
Focus on ensuring equitable vaccination access across the entire population. Monitor vaccine uptake and coverage, and reassess strategies to increase uptake in populations or communities with low coverage.

Phase 3 will begin as COVID-19 vaccine increases in widespread availability. It is likely that COVID-19 vaccine supply will equal demand and vaccine administration networks will support increased access. KDPH will:

• Continue to focus on equitable vaccination access to vaccination services;
• Monitor COVID-19 vaccine uptake and coverage in critical populations and target strategies to reach populations with low vaccination uptake or coverage;
• Partner with commercial and private entities to ensure COVID-19 vaccine and vaccination services are widely available; and
• Monitor supply and reposition vaccine products to minimize vaccine wastage.

Phase 4: Sufficient Supply of vaccine doses to meet or exceed demand
Focus on ensuring equitable vaccination access across the entire population. Target vaccine uptake in populations or communities with low coverage.

Phase 4 will begin as COVID-19 vaccine becomes widely available and integrated into routine vaccination programs. It is likely that COVID-19 vaccine supply will exceed demand and vaccine administration networks may shift to a routine immunization strategy.
The ACIP Example of Phase 1 & Phase 2 COVID-19 vaccination roll-out

https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-20/03-COVID-Oliver.pdf
SECTION 4: CRITICAL POPULATIONS

Identification of Target Groups

It is important to acknowledge that a critical difference between the current pandemic (COVID-19) and the context envisioned in the CDC’s “2018 guidance for pandemic influenza vaccine allocation” is not only the epidemiological differences between COVID-19 and influenza, such as the higher rates of asymptomatic transmission and fatality risk, but also that we are currently in the midst of a social justice movement across the country.

Minimizing COVID-19 illness and deaths is a primary goal of vaccination, but this is not the only dimension of wellbeing and common good that should be considered. Health, economic stability, and social connection are all central to wellbeing, for both individuals and communities. Thus, promoting wellbeing and the common good involves not only promoting public health but also promoting economic and social wellbeing. This is reflected in a statement in the CDC’s 2018 pandemic influenza vaccine allocation document: “The overarching objectives guiding vaccine allocation and use during a pandemic are to reduce the impact of the pandemic on health and minimize disruption to society and the economy.”

The CDC’s Advisory Committee on Immunization Practices (ACIP), the National Institutes of Health (NIH), and the National Academies of Sciences, Engineering, and Medicine (NASEM) are working to determine populations of focus for COVID-19 vaccination and ensure equity in access to COVID-19 vaccination availability across the United States. CDC has established an ACIP work group to review evidence on COVID-19 epidemiology and burden as well as COVID-19 vaccine safety, vaccine efficacy, evidence quality, and implementation issues to inform recommendations for COVID-19 vaccination policy.

KDPH established a Vaccination Allocation Committee (VAC) in which the members review the CDC’s recommended target populations and adjust as necessary. The tasks for the committee include reviewing allocation priorities, and the populations that will be added successively as vaccine supplies increase. Among the factors that the committee is expecting to consider are: health disparities and other health access issues; individuals at higher risk (e.g., elderly and those with underlying health conditions); occupations at higher risk (e.g., health care workers and essential industries); populations at higher risk (e.g., racial and ethnic groups, incarcerated individuals, and residents of nursing homes); and geographic distribution of active virus spread. It is likely that KDPH’s recommendations for vaccine prioritization will reflect the recommendations set forth by the CDC’s advisory committee with minimal changes. KDPH recognizes, though, the potential for alterations of these recommendations based on the evolving epidemiology of COVID-19 and will monitor national recommendations for changes that may occur.

The Advisory Committee on Immunization Practices (ACIP) Phase 1a Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends that, when supplies of COVID-19 vaccine are limited, vaccination should be offered in a phased approach. On Dec. 1st, the CDC Advisory Council on Immunization Practices (ACIP) voted to approve the recommendation of frontline healthcare workers and long-term care facility staff & residents as priority groups to receive initial doses of vaccine once approved by the FDA.
Per ACIP, health care workers are paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials. For Phase 1a, this includes individuals providing patient care in settings such as:

- Hospitals
- Long-term care facilities
- Emergency medical services
- Outpatient clinics
- Home health care
- Pharmacies
- Public health
- Education (e.g., school nurses and healthcare personnel)

**Phased Allocation of COVID-19 Vaccines Phase 1a ACIP Meeting 12-20-20**

<table>
<thead>
<tr>
<th>Health care Personnel(^1,2) (HCP) (\sim 21\text{ million})</th>
<th>Long-Term Care Facility (LTCF) Residents(^3) (\sim 3\text{M})</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hospitals</td>
<td>• Skilled nursing facilities (\sim 1.3\text{ M beds})</td>
</tr>
<tr>
<td>• Long-term care facilities</td>
<td>• Assisted living facilities (\sim 0.8\text{ M beds})</td>
</tr>
<tr>
<td>• Outpatient clinics</td>
<td>• Other residential care (\sim 0.9\text{ M beds})</td>
</tr>
<tr>
<td>• Home health care</td>
<td></td>
</tr>
<tr>
<td>• Pharmacies</td>
<td></td>
</tr>
<tr>
<td>• Emergency medical services</td>
<td></td>
</tr>
<tr>
<td>• Public health</td>
<td></td>
</tr>
</tbody>
</table>

**Kentucky- Phase 1a**

Kentucky planned for very small initial allocations of vaccine when product first becomes available. ACIP recommended 1) health care personnel and 2) residents of long-term care facilities (LTCFs) be offered vaccination in Phase 1a of the COVID-19 vaccination program. Kentucky adopted these recommendations. KDPH recognizes the sub-prioritization approach recommended by ACIP, because initial vaccine allocation is scarce compared to the number of healthcare personnel in the state who would require vaccination, and there is expected to be a continued constrained supply environment for some months. In addition to the sub-prioritization endorsed by ACIP, KDPH is including additional sub-prioritization categories to better inform providers to ensure ethical allocation of scarce vaccine.
Initial allocation of vaccine in Phase 1a is being distributed to hospitals, which are responsible for vaccinating healthcare personnel, and the Pharmacy Partnership for Long-Term Care Program, which is responsible for vaccinating residents and healthcare personnel who work in long-term care facilities.

As more is known about vaccine availability, state and local health officials will be able to determine the most effective and equitable way to provide vaccinations to other prioritized groups. KDPH may work with LHDs and other stakeholders to develop a pre-screening process.

**Healthcare Personnel:** “Health care personnel” are defined by ACIP as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials. These health care personnel may include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, therapists, phlebotomists, pharmacists, students and trainees, direct support professionals, clinical personnel in school settings or correctional facilities, contractual staff not employed by the health care facility, and persons (e.g., clerical, dietary, environmental services, laundry, security, maintenance, engineering and facilities management, administrative, billing, and volunteer personnel) not directly involved in patient care but potentially exposed to infectious agents that can be transmitted among from healthcare personnel and patients. “Healthcare settings” refers to the CDC definition, of the places where healthcare is delivered and includes, but is not limited to, acute care facilities, long term care facilities, inpatient rehabilitation facilities, nursing home and assisted living facilities, home healthcare, vehicles where healthcare is delivered (e.g., mobile clinics), and outpatient facilities, such as dialysis centers, physician offices, adult day facilities and others.

**Sub-prioritization of Healthcare Personnel:** ACIP recommends that healthcare personnel be prioritized in the earliest phases of COVID-19 vaccination. However, since there is insufficient supply to cover all healthcare personnel, ACIP has recommended further sub-prioritization. As such, “COVID-19 facing healthcare personnel,” should be prioritized. Healthcare providers prioritized for vaccination in Phase 1a should be those with the greatest occupational risk for exposure to and/or transmission of SARS-CoV-2. Examples of prioritized high-risk healthcare workers include (in no specific priority order):

- Home health/hospice workers not vaccinated by hospitals or healthcare systems
- Emergency Medical Services responders
- Pharmacists
- Primary care practitioners including family medicine and general medicine providers Freestanding EDs, urgent care, pharmacies, oncology clinics, and dialysis centers not vaccinated by hospitals or healthcare systems
- OB-GYN practitioners not vaccinated by hospitals or healthcare systems
- Federally Qualified Health Center providers
- Surgeons not vaccinated by hospitals or healthcare systems
- Mobile unit practitioners
- Healthcare providers, including public health employees, at risk for exposure to and/or transmission of SARS-CoV-2, such as vaccinators.
- Dental providers
- Other high-risk services/activities that may be covered under Phase 1a
  - Environmental cleaning of patient care areas
  - Laboratory processing of COVID-19 specimens
  - Mortuary care for deceased COVID-19 persons
Long-term care facilities (LTCFs): “Long-term care facilities” are defined by ACIP as facilities that provide a spectrum of medical and non-medical services to frail or older adults unable to reside independently in the community. In Kentucky facilities that may serve frail or older adults in a residential setting include: Skilled Nursing Facilities, Personal Care Homes, Assisted Living Facilities, Private Intermediate Care Facilities for Individuals with Developmental Disabilities, Community Group Homes, Residential Treatment Facilities for Adults, Long-term Structured Residences, State Veterans Homes, State Centers, private psychiatric hospitals, and State Hospitals.

Kentucky chose to utilize the “Federal Long-term Care Facility Retail Pharmacy Partnership” as the primary method of vaccination for staff and residents in a LTCF. More information on this program is in: "Section 6: Vaccine Administration Capacity, Federal LTCF Retail Pharmacy Partnership"

Sub-prioritization of LTCFs: ACIP recommends that LTCF residents be prioritized in the earliest phases of COVID-19 vaccination. LTCF staff are considered healthcare personnel. However, in settings where initial vaccine is insufficient to vaccinate residents of all LTCFs, ACIP recommends further sub prioritization.

- Skilled Nursing Facilities should be prioritized among LTCFs as they provide care to the most medically vulnerable residents.
- After skilled nursing facilities have been vaccinated, the remaining LTCFs should be prioritized by licensure type based on factors related to COVID-19 infection risk.
- Residents of congregate settings and individuals receiving home and community-based services not otherwise specified as a LTCF and/or not participating in Federal LTCF Pharmacy Partnership

* Phases are subject to change and are listed for planning purposes only

<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 A</td>
<td>Long term care facilities, assisted living facilities, health care personnel</td>
</tr>
<tr>
<td>1 B</td>
<td>First responders, anyone age 70 or older, Kentucky K-12 school personnel</td>
</tr>
<tr>
<td>1 C</td>
<td>Anyone age 60 or older, anyone age 16 or older with CDC highest risk C19 risk conditions, all essential workers</td>
</tr>
<tr>
<td>2</td>
<td>Anyone age 40 or older.</td>
</tr>
<tr>
<td>3</td>
<td>Anyone age 16 or older.</td>
</tr>
<tr>
<td>4</td>
<td>Children under the age of 16 if the vaccine is approved for this age group (est. 18% of KY population)</td>
</tr>
</tbody>
</table>

**Kentucky-Phase 1b**

* Phase 1b Target Groups are subject to change and are listed for planning purposes only. Target groups are listed in no particular order*.

**Adults 70 and older:** Age associated high risk
- People age 70 years and older

**First Responders and Protective Service Occupations:** On scene, cannot work remotely or maintain social distancing
- Law enforcement
  - Personnel with direct public contact and possible COVID-19 exposure
- Fire/rescue personnel (not vaccinated as an EMS worker in Phase 1a)
  - Personnel with direct public contact and possible COVID-19 exposure
- Corrections personnel
  - Personnel at risk for possible COVID-19 exposure
- Older Adult Protective Services, Adult Protective Services, Child Protective Services
  - Personnel with direct public contact and possible COVID-19 exposure

**K-12 Educators and support staff**
- Teachers
- Pupil Transport
- School administrative and support staff (clerks, sanitation, food service)

**Kentucky-Phase 1c**

* Phase 1c Target Groups are subject to change and are listed for planning purposes only* * Target groups are listed in no particular order*.

**Adults 60 and Older:** Age associated high risk
- Any person 60 years and older

**Persons aged > 16 years old with CDC Identified “Highest Risk Medical Conditions”:** People with high risk conditions leading to more severe disease and poor outcomes if infected with COVID-19. The CDC has identified medical conditions or risk behaviors that are associated with increased risk for severe COVID-19. The risk for COVID-19–associated hospitalization increases with the number of high-risk medical conditions, from 2.5 times the risk for hospitalization for persons with one condition to 5 times the risk for those with three or more conditions, such as:
  - Underlying Medical Conditions
  - Cancer
- Chronic kidney disease
- COPD (chronic obstructive pulmonary disease)
- Immunocompromised state (weakened immune system) from solid organ transplant
- Obesity (body mass index [BMI] of 30 kg/m² or higher but less than 40)
  - Severe obesity (BMI of 40 kg/m² or higher)
- Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- Sickle cell disease
- Type 2 diabetes mellitus
- Pregnancy

**All Essential Workers**

Kentucky has chosen to concurrently vaccinate “Frontline Essential Workers” and “Essential Workers” during Phase 1c.

- **Frontline Essential Workers and Essential Workers**: ACIP used Cybersecurity & Infrastructure Security Agency’s (CISA) guidance, to define “Frontline Essential Workers” as the subset of essential workers likely at highest risk for work-related exposure to SARS-CoV-2, the virus that causes COVID-19, because their work-related duties must be performed on-site and involve being in close proximity (<6 feet) to the public or to coworkers, such as: First Responders (Firefighters, Police), Education (teachers and school-based personnel not included in 1b), Child Care Staff, Food and Agriculture, Manufacturing, Corrections workers, U.S. Postal Service workers, public transit workers, and grocery store workers. “Essential workers” refers to the ACIP’s definition and is based off of CISA guidance. CISA has developed a list intended to guide jurisdictions in identifying essential critical infrastructure workers, who may be exempted during stay-at-home-orders. An example of “Essential Workers includes those in transportation and logistics, water and wastewater, food service, shelter and housing (e.g., construction), finance (e.g., bank tellers), information technology and communications, energy, legal, media, public safety (e.g., engineers), and public health workers. For more information see: Interim Considerations for Phased Implementation of COVID-19 Vaccination and Sub-Prioritization Among Recommended Populations

**Kentucky-Phase 2**

**Persons aged ≥40 years old**: Persons aged ≥40 years old not already recommended for vaccination in previous phases.

**Kentucky-Phase 3**

**All other persons aged ≥16 years old**: Includes all other persons aged ≥16 years old not already recommended for vaccination in previous phases

**Kentucky-Phase 4**
Children under the age of 16: Phase 4 includes children under the age of 16 (if the vaccine is approved for this age group).

Transitioning Between Vaccination Phases

Considerations for transitioning between phases are being developed to ensure expeditious transition from one phase of COVID-19 vaccine allocation to the next (i.e., from Phase 1a to 1b or from Phase 1b to 1c) as vaccine supply increases and exceeds demand within specific populations or geographic locations in a given phase, or when low demand puts vaccine doses at risk for going unused. It is not necessary to vaccinate all individuals in one phase before initiating the next phase; phases may overlap.

Decisions regarding a formal transition from one phase to the next may be based on factors such as demographic and workforce characteristics, COVID-19 epidemiology within the jurisdiction, vaccine administration efficiency and vaccine supply and demand within the jurisdiction. KDPH will continually assess vaccine supply, demand, and equitability of vaccine distribution, and consider re-distribution of vaccine or ways to expand vaccination access, demand, and capacity, and address vaccine hesitancy within the jurisdiction.

References:
- Vaccine Recommendations and Guidelines of the ACIP
- Interim Considerations for Phased Implementation of COVID-19 Vaccination and Sub-Prioritization Among Recommended Populations
- Evidence Table for COVID-19 Vaccines Allocation in Phases 1b and 1c of the Vaccination Program

Health Equity

KDPH will ensure, to the greatest extent possible a fair, equitable, and orderly distribution of vaccine. As target groups are being vaccinated and additional vaccine stocks become available, KDPH will ensure that communities suffering disproportionately from COVID-19, including communities of color, older adults, people with disabilities, and people with comorbidities are prioritized appropriately for vaccination. KPDH will work with local community partners and providers to strategically target underserved populations for vaccinations. KDPH currently anticipates that independent and community pharmacies will be a major partner in providing vaccine to those targeted underserved areas. The CDC has indicated that COVID-19 vaccine prioritization will “be adjusted based on experience during the first wave of the COVID-19 response, data on the virus and its impact on populations and the performance of each vaccine, and the needs of the essential workforce.”
SECTION 5: VACCINATION PROVIDER RECRUITMENT AND ENROLLMENT

An adequate network of trained, technically competent COVID-19 vaccination providers in accessible settings is critical to COVID-19 Vaccination Program success. For this reason, KDPH began recruiting and enrolling COVID-19 vaccination providers in the early spring of 2020. KDPH concentrated early planning efforts engaging those vaccination providers that can rapidly vaccinate initial populations of focus. Once enrollment of critical phase one providers is completed, geographic information system (GIS) mapping will be used to identify gaps in coverage and targeted recruitment efforts will be implemented to fill those gaps.

To receive and administer the COVID-19 vaccine, providers must enroll in the COVID-19 Vaccination Program coordinated through the KPDH Immunizations Branch. Providers must sign and agree to conditions outlined in the COVID-19 Vaccination Program Provider Agreement. The CDC has made this agreement available to Kentucky for use in conducting outreach and enrolling vaccination providers. KDPH is required to collect and submit data to the CDC on each enrolled vaccination provider/site including provider type and setting, patient population (i.e., number and type of patients served), refrigerated/frozen/ultra-cold temperature storage capacity, and logistical information for receiving COVID-19 vaccine shipments.

The first priority was to enroll hospitals with emergency departments and intensive care units that would see the highest acuity patients. Enrollment then expanded to include all hospitals in the state, so that they may provide vaccine to qualifying staff. Our next priority is to ensure all health departments have completed the provider agreements and are ready to receive vaccines, and then we will focus on pharmacies, especially those in rural areas that do not have hospitals or other opportunities to access vaccines outside of the health departments. By enrolling these pharmacies, we are able to provide vaccine to many of the priority patients. While enrolling pharmacies, KDPH will concurrently enroll Federally Qualified Health Centers (FQHCs) and Rural Health Clinics (RHCs). FQHCs and RHCs will assist in expanding vaccine access to vulnerable communities. Additionally, the State may deploy or provide support to vaccination strike teams across the state that will be able to conduct on-site vaccination events for targeted populations that may not have ready access to another vaccine provider. Once hospitals pharmacies, and FQHCs/RHCs are on boarded, KDPH will begin focusing on large employers, urgent care clinics, and community providers that will be able to reach additional individuals within these priority populations. Many of the groups will be enrolled concurrently.

Provider Recruitment and Enrollment

Healthcare and Congregate Settings

KDPH is recruiting and enrolling COVID-19 vaccination providers with the assistance of the Kentucky Hospital Association (KHA), the Kentucky Health Department Association (KHDA), Kentucky Primary Care Association (KYPCA), Kentucky Medical Association (KMA), Kentucky Department of Justice (KDOJ), the Kentucky Pharmacists Association (KPhA), the Kentucky Emergency Preparedness for Aging & Long Term Care Program, and the Kentucky Board of Pharmacy (KBP). These providers will vary in types and settings to address each of the previously described phases of vaccine availability. KDPH will provide technical assistance to hospital/healthcare systems to develop their own Phase 1 vaccine administration plan to
vaccinate frontline healthcare staff. As the vaccination campaign evolves, this plan will expand to include their smaller clinics.

Community and Independent Pharmacies

The KDPH Immunizations Branch, the Kentucky Immunization Registry Coordinator, and the Emergency Preparedness Pharmacist from the Kentucky Pharmacists Association (KPhA) have been instrumental in enrolling and “on-boarding” new providers in preparation for flu season and for COVID-19 vaccination via the “outreach program.” The team primarily focused on “community and independent pharmacies.” Recruiting materials focused on the enrollment of community and independent pharmacies not currently in the program. In many rural Kentucky counties, the community pharmacist is the healthcare provider seen most frequently. This outreach program is vital to ensuring that as many pharmacies as possible participate in the COVID-19 Vaccination Program and that citizens, specifically in rural areas, have convenient access to the vaccine.

All providers wishing to participate in the COVID-19 Vaccination Program will be validated through the applicable board of licensure by the KDPH Vaccine Accountability section (VAS) staff to ensure they are eligible to participate in the program. KDPH will use an electronic database to enter the newly enrolled providers that will be updated daily. The data will be converted to excel and submitted to the CDC through VTrckS twice weekly. KDPH will provide education and training to providers upon enrollment.

Vaccination providers will sign a “provider agreement” with KDPH in which they agree to enter all vaccines administered into the Kentucky Immunization Registry (KYIR). This will enable KDPH to actively monitor vaccine ordering, usage, inventory, and waste as well as give the provider the ability to generate patient reminders to ensure a second dose of vaccine is given and recorded. Both written guidance and recorded trainings will be part of KYIR use. Completion of those trainings will be recorded and tracked in an Access database. For more information on training see: “Section 8: Vaccine Storage and Handling.”

KDPH will require that all providers complete the CDC “You Call the Shots” storage and handling training module. The provider will then send or fax a copy of the completion certificate to the KYIR Help Desk. The provider can attend a storage and handling training or choose to have an in-person site visit. The Immunizations branch will assure that the provider has the proper equipment and training before vaccine is distributed. Once COVID-19 vaccine materials are available from the CDC, FDA, and vaccine manufacturer, KDPH will provide mandatory training prior to vaccination locations receiving vaccine supplies. This training will be specific to the COVID-19 vaccines that have been approved. These trainings will be documented in the Access database. For more information on training see “Section 8: Vaccine Storage and Handling.”
SECTION 6: VACCINE ADMINISTRATION CAPACITY

Community pharmacies play an essential role in expanding vaccine access. High-risk Medicaid patients visit their pharmacies about 35 times a year and approximately 93% of Americans live within five miles of a pharmacy. Millions of patients receive the influenza and other recommended vaccines from pharmacists annually. Specifically, in the 2018-2019 flu season, one in three adult influenza vaccines were provided at a community pharmacy.

Modeling

In 2016, the CDC partnered with Battelle to analyze every state’s pandemic flu vaccination capacity for adults. Battelle worked closely with state immunization programs and pharmacy partners to construct a simulation model to assist states in pandemic planning by estimating pandemic influenza vaccine administration capacity and comparing pandemic vaccine administration scenarios with and without retail pharmacies. *(This report contains sensitive material and is not publicly available via reference site).*

Given a number of assumptions the model suggested that it may take approximately 11 weeks for non-pharmacy providers and pharmacies to administer vaccines to 80% of the adult population in Kentucky during a pandemic, assuming an unprecedented number of adult providers would enroll as pandemic vaccine providers. Even though the results do not show less time to cover 80% of the adult population with the help of pharmacies, we still believe it is important to utilize retail pharmacy vaccinators during a pandemic. The model furthermore suggested that vaccine administration capacity among pharmacists was limited by order limits, such that if more vaccine were allocated to pharmacies it would likely take less times to reach 80% adult pandemic vaccination coverage. Pharmacists are not only highly accessible (93% of Americans live within five miles of a community retail pharmacy), but they are also commonly available for longer hours and more days than non-pharmacy providers. Further, targeted enrollment and coordination with pharmacy chains and retail stores with pharmacies as pandemic vaccine providers can identify a large number of vaccine providers to substantially augment medical and public health vaccine providers. The model did not include the potential impact of mass vaccination clinic Points of Dispensing (PODs). It is suspected that the impact of PODs will be most felt during the initial stages of a vaccination campaign and can potentially help improve vaccination administration capacity, though it is unlikely that POD staffing can be sustained at maximum capacity throughout a >26 week response and public health programs will have to rely heavily on non-pharmacy and pharmacy vaccinators for the majority of vaccinations.

This model should not be viewed as a static final assessment of the likely vaccination administration capacity in Kentucky. This is an optimistic estimate of the potential capacity of Kentucky’s vaccinators during a severe pandemic. It should be viewed as a tool to help public health preparedness and immunization programs in planning for the numbers and types of providers and resources they still need to enlist in addition to their existing workforce and assets.

Vaccination Workforce

KDPH is recruiting and enrolling COVID-19 vaccination providers with the assistance of numerous state agencies and professional organizations. These providers will vary in types and settings to address each of the previously described phases of vaccine availability. KDPH will provide technical assistance to hospital/healthcare systems to develop their own Phase 1 vaccine administration plan to vaccinate frontline healthcare staff. Furthermore, pharmacists and pharmacy technicians contribute significantly to
vaccine awareness and immunization rates through clinical efforts such as patient screening and education, vaccine administration, and accurate reporting of adverse events. KDPH is working with major “chain pharmacies” and is recruiting “community and independent pharmacies” to assist in administering the vaccine. In many rural Kentucky counties, the community pharmacist is the healthcare provider seen most frequently. KDPH will continue to enroll and onboard these providers in order to ensure an expanded COVID-19 administration capacity.

KDPH plans to utilize “mobile vaccination teams” to support and provide mass vaccination clinics to defined targeted groups and populations (i.e. meat processing plants, worksites). Another objective of the mobile vaccination teams will be to deploy to areas impacted by health inequity, often referred to as “at-risk” or “vulnerable populations.” This initiative builds upon the knowledge and experience gained during the 2018 Hepatitis A Outbreak where KDPH deployed mobile vaccination teams throughout the Commonwealth. KDPH will work to integrate the mobile vaccination teams through partnerships among LHDs, health care partners, housing agencies, and Continuum of Care partners.

**Federal Pharmacy Partnership Programs**

The HHS and CDC have partnered with pharmacies to increase access to COVID-19 vaccine as more vaccines are authorized by the U.S. Food and Drug Administration for use in the United States. There are two federal pharmacy programs: The Pharmacy Partnership for Long-Term Care Program and the Federal Retail Pharmacy Partnership Strategy for COVID-19 Vaccination.

**Federal Long-term Care Facility Retail Pharmacy Partnership**

The CDC is utilizing large retail pharmacies, such as CVS and Walgreens in Phase 1 to provide vaccination to LTCFs. CDC provided instructions to LTCFs to sign up for participation in this program. Once enrolled in the program the pharmacy chains will coordinate with the LTCFs for vaccination services. Pharmacies will then receive an allocation of the vaccine from the State’s allotment. The [CDC Pharmacy Partnership for Long-Term Care Program](#) includes additional large retailers. KDPH activated the CDC Pharmacy Partnership for LTCFs in December 2020 beginning with Skilled Nursing Facilities (SNFs). It will then expand to other LTCFs as vaccine supplies become available. The State will continue to support this partnership and ensure that LTCFs are vaccinated. Upon completion, this program may support vaccinating other targeted populations. KDPH will work with pharmacies and LTCFs to complete the KDPH COVID-19 provider onboarding (if necessary) in order to receive a state allocation separately from the federal allocation.

As part of the Federal LTCF Retail Pharmacy Partnership, which is free of charge to facilities, the assigned pharmacy will:

- Schedule and coordinate on-site clinic date(s) directly with each facility. Three visits over approximately two months will likely be needed to administer both doses of vaccine and vaccinate any new residents and staff.
- Order vaccines and associated supplies (e.g., syringes, needles, personal protective equipment).
- Ensure cold chain management for vaccine.
- Provide on-site administration of vaccine.
• Report required vaccination data (approximately 20 data fields) to the local, state/territorial, and federal jurisdictions within 72 hours of administering each dose.
• Adhere to all applicable Centers for Medicare & Medicaid (CMS) COVID-19 testing requirements for LTCF staff.

More information on the program can be found here:
Understanding the Pharmacy Partnership for Long-Term Care Program
Frequently Asked Questions about COVID-19 Vaccination in Long-Term Care Facilities

Federal Retail Pharmacy Partnership Strategy for COVID-19 Vaccination

On December 2\textsuperscript{nd} the CDC provided a summary of the Federal Retail Pharmacy Partnership Strategy for COVID-19 Vaccination. Through this program, retail pharmacy partners can help jurisdictions augment access to vaccine when supply increases and vaccine is recommended beyond the initial populations. With more than 90\% of people in the United States living within five miles of a pharmacy, pharmacies have unique reach and ability to provide access to COVID-19 vaccine and support broad vaccination efforts. This program will provide critical vaccination services for the U.S. population, with vaccine administered at store locations at no cost to recipients. The program will be implemented in close coordination with jurisdictions to ensure optimal COVID-19 vaccination coverage and vaccine access nationwide. Program activation will be on a national scale, with select pharmacy partners receiving a direct allocation of COVID-19 vaccine. Timing and scale of activation (how many partners, how many stores) will depend on various factors, including supply. The federal retail pharmacy program does not include every pharmacy in the United States. Pharmacies not included in the federal program will coordinate with KDPH to become COVID-19 vaccination providers, if eligible. Program participants include chain pharmacies and networks of independent pharmacies, and pharmacies utilizing a Network Administrator. While this program wasn’t expected to be used till Phase 2, the CDC is working towards a new timeline towards the end of January 2021, during Phase 1. KDPH is currently planning for the utilization of this program. More information is forthcoming.

Modified Scope of Practice

Each state determines the permitted scope of practice for the professions it regulates, including limiting the activities or procedures a person in that profession may undertake. Scopes of practice, which are defined by state practice acts, set forth the range of services that licensed practitioners are authorized to perform. Modifying scope of practice is one strategy that states have used in responding to public health emergencies. The 2009 H1N1 influenza pandemic saw broader use of modified scope of practice by states than in prior public health emergencies. States primarily modified scope of practice to increase the numbers of vaccinators available to meet real or anticipated demand. This was primarily accomplished by expanding the types of healthcare practitioners authorized to administer seasonal and H1N1 influenza vaccinations and by increasing the age range of patients that specified healthcare practitioners could vaccinate (e.g., adding children over a certain age). Pharmacists and EMT/EMS personnel were the two groups most frequently affected by scope of practice changes during H1N1. Other strategies some states used included allowing physicians to issue standing orders permitting vaccination without issuing prescriptions to individual patients. KDPH is currently working with the appropriate state agencies to ensure that the necessary processes and procedures are in place to ensure that any modified scope of practice is safely carried out and implemented.
Reference:
ASTHO Modified Scope of Practice Toolkit 1
ASTHO Modified Scope of Practice Toolkit 2
SECTION 7: VACCINE ALLOCATION, ORDERING, DISTRIBUTION, AND INVENTORY MANAGEMENT

Allocation and Ordering

The federal government determines the amount of COVID-19 vaccine designated for each jurisdiction. The CDC allocates COVID-19 vaccine according to the following principles:

- Allocations will be calculated pro-rata based on the size of the jurisdiction’s population and the quantity of ready-to-ship doses from manufacturer(s).
- Allocation amounts will be communicated to jurisdictions weekly. These allocations will be immediately available for ordering.
- If a jurisdiction does not order the full allocation, the remainder will roll over for future ordering. Unused allocations will not be reallocated to other jurisdictions.

Using this allotment, KDPH is responsible for managing and approving orders from enrolled providers. The amount allotted is subject to change over time and may be based on critical populations recommended for vaccination, COVID-19 vaccine production and availability, and overall population of the jurisdiction. For further information on allocation strategies see “Section 4: Critical Populations” for more information.

Federal agencies and additional commercial partners will also receive allocations directly from CDC once larger volumes of vaccine are available. The CDC is currently developing procedures to ensure that jurisdictions have full visibility of COVID-19 vaccine supply and vaccination activities among these entities located within their boundaries.

Kentucky is following the vaccine request procedures as presented by CDC at the time of availability and need. All states are in need of vaccine and it is shipped as it becomes available to the states based on the percentage of the total U.S. population that resides within that state. During Phase 1 and 2, it is expected that vaccine will be shipped from the manufacturer or distributor directly to the vaccine providers. Vaccine will be distributed through McKesson to public and private providers, similar to how the Vaccines for Children Program (VFC) vaccines are currently distributed. The vaccine will be shipped using climate controlled containers and directly shipped to vaccination providers. The CDC currently states that Phase 3 and 4 vaccine distribution will be done similarly to the Vaccines for Children Program.

On October 7, 2020, the KDPH was introduced to the CDC’s Tiberius application, which is supposed to be able to make allocations based on several variables. KDPH and other states have had limited functionality of this application. Furthermore, Tiberius has been found to have some important limitations and ability.

Due to the large minimum quantity of Pfizer vaccine (975) and the cold chain challenges, Pfizer vaccine is being allocated across qualifying facilities by hand in order to minimize the need to relocate vaccine and minimize vaccine wastage. Moderna vaccine is more easily managed and is being allocated to LHDs utilizing the Tiberius algorithm.

For the two initial vaccines, two doses will be required, and the same product must be used for both doses. Two-dose vaccine allocations will be managed in the following way:
• CDC does not expect jurisdictions or federal and commercial partners to maintain physical inventory of second-dose product (i.e., jurisdictions will not be expected to store product for 21–28 days to prepare for second-dose administration).

**Distribution**

KDPH, in collaboration with Kentucky Emergency Management (KYEM), will ensure the regional and local distribution of vaccines to pre-determined sites. Local emergency management, public health, and public safety authorities, in conjunction with the state authorities, will play key roles in ensuring the safe and proper storage and handling of the vaccine. Portions of the Kentucky Medical Countermeasures Plan will be used to support vaccine distribution operations.

Although plans may change, the CDC currently assumes vaccine distribution will be managed centrally, although vaccines may be handled through more than one distributor. Distribution may be expanded to include additional healthcare organizations and vaccination providers who can provide pandemic vaccinations to targeted groups. Vaccine will be sent directly to vaccination providers (e.g. physician’s office) or designated depots for secondary distribution to administration sites (e.g. chain drug stores central distribution).

Providers willing to administer the vaccine continue to be enrolled in the Kentucky Immunization Registry (KYIR) and agree to requirements for receiving, storing, administering, and tracking vaccine administration. See “Section 5: Vaccination Provider Recruitment and Enrollment” for more detailed information on provider enrollment. Enrolled providers will place orders for the vaccine with the state immunizations program. The CDC is expected to provide each state an allocation of vaccine based on population, and states can prioritize and fill orders against those allotments. Orders are then sent to the CDC and vaccines will be shipped directly to the provider through a centralized vaccine distributor. For some critical workforce groups, KDPH and LHDs may have to coordinate separate vaccine clinics with employers. For example, hospitals or health systems may vaccinate their own workforce.

In the earliest phase, when vaccine is limited, KDPH will utilize an Excel based allocation sheet to indicate who is to receive doses from each allocation. The information in the allocation sheet is used to create vaccine orders in KYIR and then flows into VTrckS. The vaccination sites are notified that vaccines have been allocated to them and to prepare for arrival. This process requires close coordination among federal, state, local, and health care partners to ensure sites are notified of vaccine allocation and shipment information in order to be prepared to receive and administer vaccine immediately.

The storage, handling, and administration requirements of ultra-cold vaccines have presented a logistical challenge to the planning team. As a result of these challenges, ultra-cold vaccine is targeted to Hospitals with ultra-low cold storage (unless otherwise recommended by CDC). Although vaccination capacity exists to use the 975-dose minimum orders, the complicated storage requirements of ultra-cold vaccine could undermine the tiered sequencing currently planned to guarantee equitable vaccine distribution across rural and urban populations.

Kentucky plans to minimize redistribution of COVID-19 vaccine to every extent possible by ensuring appropriate allocation to vaccinating partners; however, some redistribution will be unavoidable. Redistribution will be coordinated centrally to ensure the integrity of the cold chain and, at least initially, vaccine will only be redistributed with the approval and involvement of Regional Field Representatives.
and KDPH. Depending on the circumstances, vaccine may be transported by regional emergency management staff, the local or regional health department, or by other official personnel. In some situations, KDPH may occasionally allow local transport of vaccines from one location to another if adherence to cold chain and tracking requirements are maintained. Each provider must store and handle all vaccines within proper temperature ranges. Each storage unit that would be approved to store COVID-19 vaccine must have monitored temperatures at all times using a digital data logging thermometer and all storage practices as outlined in the CDC’s Vaccine Storage and Handling Toolkit. A COVID-19 Provider will only be approved for shipment of vaccines once their storage unit (refrigerator/freezer) exhibits stable temperatures within the specified range. The CDC does not pay for or reimburse jurisdictions, COVID-19 vaccination provider organizations, facilities, or other entities for any redistribution beyond the initial designated primary CDC ship-to location, or for any vaccine-specific portable refrigerators and/or qualified containers and pack-outs. See “Section 8: COVID-19 Vaccine Storage and Handling” for more information.

Vaccine Distribution to Target Groups

Currently during Phase1 KDPH receives weekly vaccine allocations from OWS. The vaccine is then shipped by the centralized distributor, to the designated site(s). It is expected that vaccine will continue to be shipped from the manufacturer or distributor, directly to the Phase 1 target group such as a hospital or long-term care facility, LHDs and in rare cases, the KDPH warehouse. For some critical workforce groups, KDPH and LHDs may have to coordinate separate vaccine clinics with employers. For example, hospitals or health systems may vaccinate their own workforce. Phase 2 and 3 target groups could include direct shipment to LHDs that could then further distribute the vaccine to other private providers or administer the vaccine. In some local jurisdictions, the LHD may choose to also have private providers designated as ship-to sites to expedite the distribution process. KDPH will strategically allocate vaccine to target groups and local jurisdictions according to the number of persons in target groups, general population, disease burden, and other factors. Timing of shipping will follow the target scheme for allocation according to the target groups identified.

Vaccine will be administered per the phased target structure through those methods deemed most appropriate by state and local authorities. Initially, when vaccine is extremely limited, it will be direct shipped to sites where the identified target groups are located. KDPH will work in coordination with the receiving organization to ensure proper vaccine distribution and administration. These methods may include clinics at the site of the prioritized recipients, through mass clinics, and through other distribution and administration structures as best fits the needs and resources of each local community.

KDPH may also choose to administer all or some of the vaccine through state and local-run vaccination sites. If so, they may use emergency mass dispensing as a model for distribution, for which extensive plans have been developed for other threats such as anthrax.

When it is time to vaccinate the Phase 2 target groups, KDPH anticipates that LHDs may need to complete distribution on a very small scale to area providers who do not meet the minimum ship to order for McKesson. In those cases, KDPH and the LHD will work with the provider to ensure that cold chain is maintained throughout the transfer.

_Interim pandemic distribution plan, 04/20/20_
Inventory Management

KDPH will continue to maintain, on a real-time basis, a database inventory of each dose of vaccine that is shipped from the manufacturer or distributor and received at each ship-to site. Ship-to sites will maintain, on a real-time basis, an inventory of vaccine in stock, the manufacturer, lot numbers, expiration dates for each lot, and a record of each dose of vaccine transferred to any clinics designated to conduct the vaccination clinics. COVID-19 vaccination providers are required to report inventory of COVID-19 vaccines. All such data is transmitted to KDPh electronically via the KYIR, and KDPh transmits it to CDC. Inventory management is explained in further detail in “Section 9: Vaccine Administration Documentation and Reporting.”

As anticipated, initial COVID-19 vaccines were authorized under an EUA. Vaccines authorized under the EUA contain slight variations from approved Food and Drug Administration (FDA) products, including:

- **Expiration Date:** The vaccine vials and cartons will not contain a printed expiration date. Expiration dates may be updated based on vaccine stability studies occurring simultaneously with COVID-19 vaccine distribution and administration. Current expiration dates by vaccine lots for all authorized COVID-19 vaccines will be posted on a U.S. Department of Health and Human Services (HHS) website accessible to all COVID-19 vaccination providers. To ensure that information systems continue to work as expected, CDC has worked with FDA and the manufacturers to include a two-dimensional (2D) barcode on the vaccine vial (if possible) and carton (required) labels that includes a National Drug Code (NDC), lot number, and a placeholder expiration date of 12/31/9999 to be read by a scanner. The placeholder 12/31/9999 expiration date is not visible on the vaccine packaging nor found anywhere else; it is only to facilitate information system
compatibility. CDC is developing “beyond use date” (BUD) tracker labels to assist clinicians with tracking expiration dates at the point of vaccine administration. The label templates will be available on the CDC website.

- **Manufactured Date**: A manufactured date will be on the packaging and should not be used as the expiration date when documenting vaccine administration. This date is provided to help with managing stock rotations; however, expiration dates should also be considered (see above) as using manufactured date alone could have some limitations.

- **2D Barcode**: The 2D barcode available on the vaccine carton (also on the vials for some vaccines) will include NDC, lot number, and a placeholder expiration date of 12/31/9999.

- **QR Code**: Each vaccine manufacturer will include a Quick Response (QR) code on the vaccine carton for accessing FDA-authorized, vaccine product-specific EUA fact sheets for COVID-19 vaccination providers and COVID-19 vaccine recipients.

### Ancillary Supplies

COVID-19 vaccine and ancillary supplies, commonly referred as “COVID-19 Vaccination Kits” will be procured and distributed by the federal government at no cost to enrolled COVID-19 vaccination providers. COVID-19 Vaccination Kits will be sent in concert with the vaccine. Sharps containers, gloves, bandages, and other supplies will not be included.

Ancillary supplies will be packaged in kits and will be automatically ordered in amounts to match vaccine orders in **VTrckS**. Each kit will contain supplies to administer 100 doses of vaccine, including:

- Needles, 105 per kit (various sizes for the population served by the ordering vaccination provider);
- Syringes, 105 per kit;
- Alcohol prep pads, 210 per kit;
- Four surgical masks and two face shields for vaccinators, per kit; and
- COVID-19 vaccination record cards for vaccine recipients, 100 per kit.

For COVID-19 vaccines that require reconstitution with diluent or mixing with adjuvant at the point of administration, mixing kits with syringes, needles, and other needed supplies will also be included. Ancillary supply kits will not include sharps containers, gloves, and bandages. Additional personal protective equipment (PPE) may be needed depending on vaccination provider site needs.

Facilities ordering outside of Kentucky’s allocation (i.e., commercial and federal entities with federal MOUs in place) will order directly from the CDC and the CDC will be responsible for approval of those orders

### Extra Doses

On December 16th the FDA advised that it is acceptable to use every full dose obtainable (the sixth, or possibly even a seventh) from each vial, pending resolution of the issue. However, since the vaccine does not contain preservative, it is critical to note that any further remaining product that does not constitute a full dose should not be pooled from multiple vials to create one.
Pfizer submitted a request to the EUA to clarify that the number of doses obtainable per vial of Pfizer-BioNTech COVID-19 vaccine may be up to six doses. After considering Pfizer’s request, in order to provide additional flexibility to vaccine providers, FDA has updated the Letter of Authorization for the EUA for the Pfizer-BioNTech COVID-19 Vaccine to remove the reference to how many doses are contained in one vial. The Agency has also updated the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) to note that, after dilution, one vial of Pfizer-BioNTech COVID-19 Vaccine contains up to six doses of 0.3 mL. Vial labels and cartons may state that after dilution, a vial contains 5 doses of 0.3 mL. The information in the Fact Sheet regarding the number of doses per vial after dilution supersedes the number of doses stated on vial labels and cartons.

In some cases, providers may be able to obtain six doses from a vial and providers should use a sixth dose if it is obtainable. Whether a sixth dose is obtainable depends, in part, on the type of syringes and needles used to withdraw doses from the vials. Because the vaccine does not contain preservative, it is critical to note that any further remaining product that does not constitute a full dose should not be pooled from multiple vials to create one dose. This updated information in the Letter of Authorization and Fact Sheet for Healthcare Providers Administering Vaccine should address any questions or confusion about whether these additional full doses may be used.

**Vaccine Security**

Security at the “state level” will be the responsibility of KDPH who will work in coordination with the Kentucky State Police (KSP). “Local level” security operations will be the responsibility of the LHD and local law enforcement agencies. Should a LHD require security, arrangements should be made with the local law enforcement agencies. If necessary, local security operations may be supplemented by KSP. If the county believes extra security is warranted then they should work through their local emergency manager and their local law enforcement agencies and if necessary submit a resource request through KYEM.

Local law enforcement agencies will be responsible for securing fixed facilities involved in the vaccine distribution process. This includes any regional storage “nodes” and dispensing sites such as mass vaccination clinics. Local law enforcement officials should engage with LHDs and county officials in the planning process necessary to provide this security function.

When applicable, KDPH, KYEM, KSP, and the Kentucky Transportation Cabinet (KYTC) will coordinate transportation security through the SHOC and provide escorts for transport vehicles to sites and/or health care facilities. KYEM and KDPH will provide resource support such as credentials, vehicle markers, and communication devices to each driver of state-operated vehicles.
SECTION 8: VACCINE STORAGE & HANDLING

COVID-19 vaccine products are temperature-sensitive and must be stored and handled correctly to ensure efficacy and maximize shelf life. Proper storage and handling practices are critical to minimize vaccine loss and limit risk of administering COVID-19 vaccine with reduced effectiveness. Jurisdictions should work with staff at each COVID-19 vaccination provider site to ensure appropriate vaccine storage and handling procedures are established and followed.

It is expected that cold chain storage and handling requirements for COVID-19 vaccine products will vary in temperature from refrigerated (2°C to 8°C) to frozen (-15°C to -25°C) to ultra-cold (-60°C to -80°C in the freezer or within the dry ice shipping container in which product was received). Ongoing stability testing may impact these requirements. Note: These temperatures are based on information available as of September 2020. Updated information will be provided as it becomes available.

The cold chain begins at the COVID-19 vaccine manufacturing plant, includes delivery to and storage at the COVID-19 vaccination provider site, and ends with administration of COVID-19 vaccine to a person. Jurisdictions and vaccination providers are responsible for maintaining vaccine quality from the time a shipment arrives at a vaccination provider site until the dose is administered. KDPH will minimize opportunities for breaks in the cold chain. Most COVID-19 vaccine will be delivered from CDC’s centralized distributor directly to the location where the vaccine will be stored and administered, although some vaccine may be delivered to secondary depots for redistribution. Certain COVID-19 vaccine products, such as those with ultra-cold temperature requirements, will be shipped directly from the manufacturer to the vaccination provider site. KDPH does have a means to store vaccine if an “unplanned repositioning” of vaccine is required. KDPH has procured resources to assist in adhering to all cold chain requirements and has developed a partnership with a private entity should KDPH have to expand its ultra-low cold storage capacity.

Cold chain maintenance at individual provider locations will require appropriate vaccine storage and temperature monitoring equipment, a trained provider staff, and consistent, accurate inventory management as already discussed. In rare instances, some facilities will have the capacity to store vaccines under ultra-cold storage conditions. These facilities will largely be located in large medical centers and a handful of pharmacies. Facilities storing vaccines under ultra-cold conditions will be required to monitor unit temperatures with equipment that is appropriate for the monitoring of vaccines stored in that environment. Facilities with repeated temperature excursions will be closely monitored and required to submit weekly data logger reports to the program. Facilities identified as having these issues will be reviewed on a case-by-case basis and will risk having their vaccines reallocated to other facilities if these issues are not corrected or if it is determined that the facility is negligent in their handling of vaccines.

The Pfizer vaccine requires ultra-cold storage and will be shipped in containers that will require up to 150 lbs. of pelleted dry ice per 975 doses of vaccine to maintain those conditions for as long as 14 days. The KDPH Logistics Team has identified the supply chain and delivery of that resource to ensure maintenance of the cold chain. The CDC has indicated it will provide the initial recharge of dry ice, but the State is prepared to supply the dry ice in case there is a delay in the federal shipments.

The KYIR implementation team has established multiple training outlets for vaccine storage and handling. Existing quick guides and YouTube training videos on basic KYIR functionality are already embedded directly in the KYIR system. The KYIR team also plans to hold a series of live-webinars for COVID-19
providers on inventory management, mass vaccination usage, and reminder/recall functionality. Inventory management trainings have also been created in the TRAIN system that will allow those who need training on KYIR inventory management to self-register for the course and to complete the training on their own time. Offering a variety of venues for training will allow the end-user to decide which platform works best with their schedule. Internet usage and accessibility to KYIR will be determined in the early planning phases via a survey to ensure each identified partner has the necessary resources to report doses administered. Utilizing supplemental funds, the Immunization Branch will hire additional KYIR Trainers to facilitate training needs. Other trainings include the CDC webinars called “You Call the Shots – VFC” and “You Call the Shots – Storage and Handling.” All clinic staff involved with the vaccine delivery process should be required to complete the above-mentioned trainings and have a clear understanding of all storage and handling policies.

The CDC has developed an addendum to the Vaccine Storage and Handling Toolkit that specifically addresses COVID-19 vaccines. There are numerous resources that KDPH and other vaccine providers will use to ensure proper vaccine storage and handling, such as:

- COVID-19 Vaccine Storage and Handling Website
- CDC’s Vaccine Storage and Handling Toolkit
- CDC’s You Call the Shots Trainings

**Satellite, Temporary and Off-Site Clinics**

Satellite, temporary, and off-site vaccination clinics play an important role in improving vaccination coverage rates and vaccinating hard-to-reach populations. Vaccination clinics held in these settings have unique challenges and providers must follow specific guidelines for managing publicly supplied vaccine in these non-traditional settings. KDPH may establish Regional Response Command Centers (RRCCs) to help support coordination between agencies.

The CDC has been consistent in its messaging saying that states do not need to acquire ultra-low cold storage equipment. Furthermore, KDPH is working with KYEM on contingency plans in case there is a breakdown or an unplanned event that impacts the cold-chain storage ability of the CDC and its central distributor. It is anticipated that Kentucky will form a partnership or agreement with one of the three major shipping hubs that are located within the state.

KDPH and LHDs are very familiar with operating vaccination clinics, but complexities arise when dealing with a vaccine that requires ultra-low cold storage. There are numerous best practices and reference materials for off-site vaccination clinics (see Attachment 1: Vaccination Resources and Checklists ). KDPH will work with LHDs on vaccine storage and utilize the guidelines set forth in the Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations when conducting vaccination clinics. However, these situations require additional oversight and enhanced storage and handling practices, including:

- The quantity of COVID-19 vaccine transported to a satellite, temporary, or off-site COVID-19 vaccination clinic will be based on the anticipated number of COVID-19 vaccine recipients and the ability of the vaccination provider to store, handle, and possibly transport the vaccine appropriately. This is essential to minimizing the potential for vaccine wastage and spoilage.
- COVID-19 vaccines may be transported — not shipped — to a satellite, temporary, or off-site COVID-19 vaccination clinic setting using vaccine transportation procedures outlined in the
upcoming COVID-19 addendum to CDC’s Vaccine Storage and Handling Toolkit (still in development). The procedures will include transporting vaccines to and from the provider site at appropriate temperatures, using appropriate equipment, as well as monitoring and documenting temperatures.

- Upon arrival at the COVID-19 vaccination clinic site, vaccines must be stored correctly to maintain appropriate temperature throughout the clinic day.

- Temperature data must be reviewed and documented according to guidance in the upcoming COVID-19 addendum to CDC’s Vaccine Storage and Handling Toolkit (still in development).

- At the end of the clinic day, temperature data must be assessed prior to returning vaccine to fixed storage units to prevent administration of vaccines that may have been compromised.

- As with all vaccines, if COVID-19 vaccines are exposed to temperature excursions at any time, the temperature excursion should be documented, reported, and acted upon according to the immunization program’s procedures.
SECTION 9: VACCINE ADMINISTRATION, DOCUMENTATION AND REPORTING

COVID-19 Vaccine Providers will be required to submit data to the Kentucky Immunization Registry (KYIR). If the facility has an existing electronic HL7 connection through the Kentucky Health Information Exchange (KHIE) then this will be the preferred method of receiving data. If a facility is not yet on-boarded with KHIE for electronic data submission of immunization data, or does not have the resources to onboard with KHIE, then manual data entry to the KYIR will be required. COVID-19 providers manually entering administered vaccines in KYIR will be encouraged to use the Mass Vaccination module in order to reduce the steps involved in documentation. Non-traditional vaccinators and larger federal sites, such as the Department of Defense, are expected to onboard directly to the IZ Gateway. It is still to be determined if data will be submitted to CDC through the IZ Gateway or through an electronic file upload. The KYIR team is working closely with its IIS (e.g., immunization information system) vendor to determine the most efficient way of providing necessary data through a file method to CDC, if needed. Final decisions will be based on further information provided by the CDC.

KDPH must be able to ensure that each COVID-19 vaccination provider is ready and able to report the appropriate data elements. Multiple training outlets have been established by the KYIR implementation team. Existing quick guides and YouTube training videos on basic KYIR functionality are already embedded directly in the KYIR system. The KYIR team also plans to hold a series of live-webinars for COVID-19 providers on inventory management, mass vaccination usage, and reminder/recall functionality. Inventory management trainings have also been created in the TRAIN system, which will allow those who need training on KYIR inventory management to self-register for the course and complete the training on their own time. Offering a variety of venues for training will allow the end-user to decide which platform works best with their schedule. Internet usage and accessibility to KYIR will be determined in the early planning phases via a survey to ensure each identified partner has the necessary resources to report doses administered.

Satellite, temporary, and off-site vaccination clinics play an important role in improving vaccination coverage rates and vaccinating hard-to-reach populations. Vaccination clinics held in these settings have unique challenges and providers must follow specific guidelines for managing publicly supplied vaccine in these non-traditional settings. KDPH must ensure that providers have the ability to ensure real-time documentation and reporting of COVID-19 vaccine administration data from satellite, temporary, or off-site clinic settings. Access to internet during off site clinics will be provided by a combination of services, including Wi-Fi “hotspots” and cellular cradle point devices. However, if data cannot be entered into KYIR during off site or satellite clinics, then the clinic will have to document doses administered once back in the office. Documentation must be entered within 24 hours of the conclusion of the clinic to meet CDC reporting requirements.

KDPH will monitor provider-level data to ensure each dose of COVID-19 vaccine administered is fully documented and reported every 24 hours. KYIR Data Quality Analyst and KYIR on-boarders will utilize internal reports from KYIR to monitor data quality and timeliness of data submission for COVID-19 providers. If data is not submitted in a timely manner, notice will be sent via email or phone call to instruct the vaccine provider on the requirements of reporting data to KYIR. The Vaccine Accountability Section (VAS) team will also assist in monitoring providers’ HL7 electronic feed while checking reconciliations prior to approving COVID-19 vaccine orders in KYIR. If issues with a clinic’s data feed arise, the VAS
representative will notify the KYIR Data Quality Analyst who will then troubleshoot connection concerns with the KYIR on-boarders. KDPH coverage reports will be generated directly out of KYIR. The Immunization Branch will utilize coverage reports to identify pockets of need and monitor vaccine uptake.

**Tracking and Monitoring Vaccination, CDC Webinar September 2020**

---

**COVID-19 Vaccine IT Overview: Vaccine Allocation, Distribution, Administration, Data, and Reporting**

The COVID-19 vaccine campaign requires unprecedented logistics and coordination effort among public health authorities and private-sector partners. Integrated IT systems — both public and private, as well as new and existing — are needed to ensure successful vaccine allocation, distribution, administration, monitoring, and reporting.

**Current CDC supported systems for vaccine logistics and administration:**

- Vaccine Tracking System
The Vaccine Tracking System (VTrckS) is the CDC’s vaccine order management system, which supports routine vaccination with almost 80 million doses of vaccine annually. CDC will use VTrckS as its platform for ordering all COVID-19 vaccines.

- **VaccineFinder**
  - The VaccineFinder website helps people find providers who offer select vaccines. VaccineFinder also allows healthcare providers to list their vaccination locations in a centralized, searchable database and to track vaccine supply. VaccineFinder will serve two roles in the COVID-19 vaccination program:
    - **Inventory reporting** (required for all COVID-19 vaccine providers): Providers will report on-hand COVID-19 vaccine inventory each day through VaccineFinder.
    - **Increase access to COVID-19 vaccines** (optional for COVID-19 vaccine providers): Once there is enough supply, COVID-19 vaccination providers may choose to make their location visible on VaccineFinder, making it easier for the public to find provider locations that have COVID-19 vaccine available. CDC will direct the public to use VaccineFinder to find locations offering COVID-19 vaccine.

- **IZ Gateway**
  - The IZ Gateway is a cloud-based message routing service intended to enable data exchange between IISs, other provider systems, and the IZ Data Lake. The IZ Gateway enables centralized data exchange and eliminates the need for multiple, individual, point-to-point connections. The IZ Gateway enables IISs, federal agencies, and providers to update, query, and report immunization data.
  - The IZ Gateway allows:
    - IISs to report data to the COVID-19 Data Clearinghouse
    - Cross-jurisdictional queries and data exchange
    - Multijurisdictional providers to share data with multiple IISs via a central connection

### New CDC systems developed for COVID-19 vaccination data collection and reporting:

- **Immunization Data Clearinghouse**
  - The COVID-19 Data Clearinghouse is a cloud-hosted data repository that receives, deduplicates, and deidentifies COVID-19 vaccination data that are then used to populate the IZ Data Lake with deidentified data for analytics.

- **Immunization Data Lake**
  - The IZ Data Lake is a cloud-hosted data repository to receive, store, manage, and analyze deidentified COVID-19 vaccination data. CDC, jurisdictions, federal agencies, and pharmacy partners will use the IZ Data Lake to store and process administration, coverage, logistics, inventory, ordering, distribution, and provider data. IISs, pharmacies, VTrckS, and VaccineFinder will provide data for the IZ Data Lake. The IZ Data Lake will also aggregate and analyze data and provide data summaries and analytics via these reporting hubs:
    - Data Storefront
    - Department of Health and Human Services’ HHS Protect data hub
• Operation Warp Speed’s Tiberius platform, a COVID-19 vaccine distribution planning, tracking, modeling, and analysis application

• **Tiberius**
  - Tiberius is the “eyes and ears” of the entire COVID-19 vaccination tracking operation, drawing directly from the COVID-19 Data Lake and in-transit data on shipments. Software tailored for Operation Warp Speed by government data contractor Palantir, Tiberius combines logistics information with census data to coordinate distribution of the vaccine. Tiberius is what Operation Warp Speed and the CDC will use to calculate jurisdictions weekly vaccine allotments taking into account inventory, storage capacity and target populations. The idea is to keep vaccine doses from piling up or getting wasted between the manufacturer and the vaccination site. Some of Tiberius’s additional features include incident management, planning, tracking, data visualization and modeling. These features help with decisions such as how and when to distribute doses to counties or hospitals based on the numbers of front-line health care workers or residents of long-term care facilities.

**References:**
- [COVID-19 Vaccination Reporting Overview](#)
- [COVID-19 Vaccine Tracking Q&As for IIS Awardees](#)
SECTION 10: VACCINE SECOND DOSE REMINDERS

Some vaccines for COVID-19 will require two doses, administered approximately two to three weeks apart, to produce an adequate immune response. Recommendations on the number of required doses and the timing of the second dose will be issued once immunogenicity trials have been completed.

If two doses are required, it will be necessary to ensure that vaccinated persons return to the same location at which they received the first dose for the second dose. KDPH, along with local health departments/districts, will arrange for information about the need for a second dose to be provided to recipients at the time of initial vaccination.

COVID-19 Providers will be encouraged to schedule the patient’s second-dose appointment when delivering their first dose. The CDC says that vaccination “verifications and reminder cards” will be included in the vaccine shipments and that providers will be required to provide vaccination cards to those receiving their COVID-19 vaccination.

Many providers will be using EHRs for all vaccination reporting. Some EHR systems have reminder recall as well. Other providers will utilize the same systems they use in their day-today reminder activities or platforms provided by pharmaceutical companies. Since many patients will be captured within both KYIR and EHR systems, some redundancy in reminder recall contact methods is expected.

Lastly, the CDC system called “VaxText” is a free text messaging platform that providers can offer to their patients. Patients can opt in to conveniently receive text message reminders to get their second dose of COVID-19 vaccine. VaxText offers the added benefit of reminding patients to sign up for v-safe, a tool that allows people to report adverse outcomes following vaccination. The VaxText text messaging resource is a free, no cost to the provider or patient, service that providers can offer to vaccine recipients if they do not already have a text or email reminder system in place. The VaxText text messaging service will ask vaccine recipients who participate for basic vaccination information (i.e., vaccination date, COVID-19 vaccine name) so it can provide reminders based on the correct vaccination schedule (e.g., 21 or 28 days between first and second doses). The VaxText service will not collect any personally identifiable information or personal health information from users and users can opt out. Vaccine recipients that participate will also receive information on COVID-19 vaccines, links to additional information on the CDC website and a prompt to sign up for “v-safe”, CDC’s new active vaccine safety monitoring system.
SECTION 11: IMMUNIZATION INFORMATION SYSTEMS

Immunization registries, also known as immunization information systems (IIS), are defined by the CDC as confidential, population-based, computerized databases that record all immunization doses administered by participating providers to persons residing within a given geopolitical area. Immunization registries offer a consolidation of patient immunization records. Compiling all immunizations in one database allows easy access for healthcare providers. Certificates for proof of immunization are also easier to obtain for the purposes of school and childcare centers. The registry also offers timely reminders for vaccines coming due for patients. The Kentucky Immunization Registry (KYIR) is KDPH’s IIS. The KYIR has many functionalities, but during the COVID-19 Vaccination Program it will be primarily used to:

- Preregister or enroll in the COVID-19 Vaccination Program;
- Place orders for COVID-19 vaccine;
- Document vaccine administration;
- Manage and report vaccine inventory;
- Report vaccine spoilage/wastage; and
- Provide reminders to COVID-19 vaccine recipients indicating when the next dose of a multi-dose vaccine is due.

The KYIR is able to capture standard data elements submitted via an HL7 message, including patient demographic information such as name, DOB, race, ethnicity, address, sex, etc. KYIR is also able to capture and store detailed vaccine administration information such as CVX, lot number, vaccine expiration date, precautions and contraindications, and additional data requirements set by the CDC. KDPH plans to capture two optional fields – race and ethnicity – during the COVID-19 vaccination campaign.

Data Exchange

The Kentucky Health Information Exchange (KHIE) automates the reporting of immunizations directly to the KYIR in support of eligible hospitals (EHs), critical access hospitals (CAHs) and eligible providers (EPs) for all stages of Meaningful Use of electronic health record technology. For the purpose of sending and receiving immunization data, the Kentucky Immunization Registry has implemented an interface that strictly adheres to the CDC and Health Level Seven (HL7) Standards as well as specific constraints recommended in the “WebIZ Immunization Registry Local Implementation Guide for HL7 2.5.1.” WebIZ is Kentucky’s immunization registry system implemented at the state level, known as KYIR. All HL7 connections are facilitated through KHIE. All onboarding capacities to establish electronic connections will be determined by the resources offered by KHIE. KYIR is cloud-hosted and has ample capacity for data storing. The KYIR team is working closely with its vendor to improve data extraction methodologies. Kentucky has already signed the data use agreements (DUA) needed for the “Connect” piece and the “Share” piece of the IZ Gateway. KDPH was fully on-boarded with the Gateway by the end of September, putting us ahead of schedule. The DUA with the Association of Public Health Laboratories (APHL) to participate in the IZ Gateway is completed, but the DUA with the CDC for national coverage analyses is not yet available. Further IIS and HL7 technical information.
**Onboarding**

KDPh is aggressively recruiting and enrolling COVID-19 vaccination providers with the assistance of multiple partner organizations. See “Section 5: Provider Recruitment and Enrollment” for more detailed information. The Immunizations Branch has hired additional individuals to assist with the increase of KYIR enrollments. KHIE will work with KYIR onboarding staff to increase onboarding efforts as well.

The KYIR on-boarders will utilize the on-boarding module in KYIR to streamline the process. The onboarding module allows the EHR technical contacts to troubleshoot issues with message formatting and data independently, reducing some of the labor intensive review conducted by KYIR on-boarders directly. KYIR staff are currently reviewing existing connections with emphasis on providers (e.g., hospital systems) who will be responsible for COVID-19 vaccination response in the early phases to confirm that data is being submitted consistently.

**Data Quality**

The KYIR on-boarding team has put a significant emphasis on ensuring the required data fields listed by the CDC are accurately captured during the onboarding process. The KYIR staff will utilize the reporting system in KYIR to frequently monitor data submission and quality. To ensure data is available, complete, timely, valid, accurate, consistent, and unique, KDPH will:

**Completeness**

- Review the Data Quality – Statistics report for whatever timeframe is required to analyze the necessary quantity of data (preferably at least 40 patients worth of data).
- Confirm that patient and vaccination data completeness listed on the Data Quality – Statistics report reaches program standards as spelled out in the Recommendations for KYIR Completeness Measure Thresholds document.
- Review the HL7 message log to ensure that there are no issues or anomalies that affect completeness.

**Accuracy**

- Review the HL7 message log in QA and confirm that commonly confused CVX codes are being entered correctly.
- Review the HL7 message log in QA and confirm that accuracy of lot numbers (i.e. not placeholders).
- Review at least 40 random patient charts with clinic staff to confirm accuracy. If data is inaccurate, work with clinic to address any issues.
- Review HL7 message log for eligibility and funding source compatibility.
- Review the HL7 message log to ensure that data being received is logical.

**Validity**

- Review the HL7 message log and individual messages for syntax quality.
- Review the HL7 message log for fields that contain contradictory values.
Review the HL7 message log for VFC facility ID associations. Confirm their validity by ensuring that data is available in reports for the VFC clinic.

**Consistency**

- Review the HL7 message log for both quantity and contents of messages to confirm that they accurately reflect the source.
- Confirm that we are receiving both new and historical immunizations, in accordance with what would be considered normal for the sending provider.

**Timeliness**

- Review the Data Quality – Statistics report for a timeframe appropriate for the quality and quantity ascertained when reviewing the HL7 message log. Confirm that vaccination event recording reaches program standards of timeliness. 95-100% of vaccinations should be entered into KYIR less than 24 hours of the vaccine being administered.

**Documentation**

- KYIR on-boarders will document the process in SharePoint and document the go-live.
- Data Quality Analyst will document the data quality review process.

**Immediately Post-Go Live** (one to two weeks, performed by assigned KYIR on-boarder and data quality analyst)

- Continue review for message quality and quantity consistency in the HL7 message log and through the Data Quality – Statistics report.

**References:**

- [CDC About Immunization Information Systems](https://www.cdc.gov/vaccines/programs/immunization-information-systems/about.html)
- [Health Level 7 (HL7)](https://www.hl7.org)
- [CDC Meaningful Use](https://www.cdc.gov/clinicsurveillance/meaningful-use/)
- [Vaccines For Children](https://www.cdc.gov/vaccines/)
SECTION 12: VACCINATION COMMUNICATION

Vaccine hesitancy was declared a top 10 global health threat by the World Health Organization in 2019. In the United States, public reluctance to be vaccinated is expanding: Recent measles outbreaks reflect parental concerns about vaccines, and each year, many adults refuse the seasonal influenza vaccine or get it late. It is very likely that public health officials and politicians will compete against an anti-vaccination movement that floods social media with misinformation, conspiracy theories and propaganda aimed at convincing people to not receive the COVID-19 vaccine. Therefore, it is of the upmost importance to have coordinated public education and communication about the COVID-19 vaccine. It should be noted that KDPH is committed to providing the public a transparent and evidence based communication strategy.

The Kentucky Strategic National Stockpile (SNS) Crisis Communication Guide was created to assist state and regional public health personnel in their response to a public emergency. The Kentucky SNS Crisis Communication Guide will serve as a resource for public communication during the COVID-19 vaccination campaign. KDPH, in cooperation with the Cabinet for Health and Family Services (CHFS), will provide public information for the media and the citizens of Kentucky. The CDC has stated that it will develop COVID-19 communication resources for organizations and jurisdictions to use with key audiences and that these resources will be available on a public-facing website currently under development, however, KDPH will likely need to tailor messaging and resources specific to special populations in Kentucky communities. KDPH will incorporate the CDC’s communication resources into its public communication efforts when applicable. Information may be disseminated via social media, web site postings, interviews, newspaper editorials, flyers, billboards, television and radio broadcasts.

KDPH decided on a “multi-front” communication strategy utilizing the KDPH Commissioner’s Office, the CHFS Office of Public Affairs, the Governor’s Office, external partners, and a strategic communications agency to ensure effective messaging across all populations. Furthermore, social, behavioral, and compliance practices and trends will be assessed in an effort to ensure accurate, proactive, time-sensitive, real-time messaging.

In order to understand Kentuckians attitude about the potential COVID-19 vaccine KDPH worked with external partners to develop a statewide assessment of public and provider attitudes and beliefs surrounding the COVID-19 vaccine. The assessment will be used to collect actionable information from the public that can be used to maximize COVID-19 vaccination uptake in Kentucky, including but not limited to information specific to subpopulations including rural, urban, African-American, and Hispanic Kentuckians. Information and data obtained via the survey will be used to assist KDPH and our partners with the development of appropriate messaging and delivery mechanisms for the public and for healthcare providers.

Clear communication is essential in building momentum for vaccine up-take and to minimize the spread of COVID-19 in the near term. Kentucky is utilizing a strategic communications agency to support outreach and communication across the Commonwealth. The Agency is providing direction, and executing a COVID-19 vaccination awareness campaign designed to emphasize equitable distribution; focus on minority and Appalachian populations and to other targeted audiences, including district and local health departments, community partners and advocates; allay concerns about taking the vaccine, and support education efforts. Outreach to Kentuckians has been modified in this campaign to be 100% contactless, with tactics limited to out-of-home and digital. Unique hash tags and a Team Kentucky-branded look and feel will provide campaign continuity, with intentional fluidity of messaging to accommodate messaging as
information becomes available. The campaign is expected to be visible until at least the third quarter of 2021. Its underpinnings include consumer research, digital advertising and social media strategy. Later this year, the campaign may be expanded to include short and longer form video and motion graphics. Kentuckians’ attitudes and reception to the vaccine are being closely observed, and later phases of the campaign will be tweaked as necessary to encourage specific calls to action.

LHDs will play an important role in identifying partners to help further disseminate messaging to communicate vaccine safety, efficacy, and importance. By establishing communication channels with local experts, the Department will be able to better target messages across the state to a diverse set of audiences. The following phased approach may be used to structure communication and outreach efforts:

- Phase 1: Potentially Limited Doses Available. Messaging will be targeted at priority groups utilizing GIS tools with data layers, best practices established in local jurisdictions, and available messaging from federal partners.
- Phase 2: Large Number of Doses Available, Supply Likely to Meet Demand. Additional messaging will be implemented to target additional priority groups that may have been disproportionately impacted by COVID-19 and live in underserved areas with lower vaccine uptake.
- Phase 3: Likely Sufficient Supply, Slowing Demand. Messaging may focus on the social responsibility of protecting loved ones, essential workers, and other vulnerable community members.

KDPH COVID-19 Vaccination Communication Objectives

- Educate the public about the development, authorization, distribution, and execution of COVID-19 vaccines and that situations are continually evolving.
- Ensure public confidence in the approval or authorization process, safety, and efficacy of COVID-19 vaccines.
- Help the public to understand key differences in FDA emergency use authorization and FDA approval (i.e., licensure).
- Engage in dialogue with internal and external partners to understand their key considerations and needs related to COVID-19 vaccine program implementation.
- Ensure active, timely, accessible, and effective public health and safety messaging along with outreach to key state/local partners and the public about COVID-19 vaccines.
- Provide guidance to local health departments, clinicians, and other hosts of COVID-19 vaccination provider locations.
- Track and monitor public receptiveness to COVID-19 vaccination messaging.

Key Audiences

KDPH will tailor messaging for each audience to ensure communication is effective. Key audiences include:

- Healthcare personnel (i.e., organizations and clinicians who will receive information about receiving and administering vaccine)
• Health insurance issuers and plans (coverage for vaccine, in-network providers)
• Employers
• Government and community partners and stakeholders
• Public/consumers
• Essential workers
  o Those in groups at risk for severe outcomes from COVID-19 infection
  o Those in groups at increased risk of acquiring or transmitting COVID-19
  o Those with limited access to vaccination services

**Call Center**

KDPH has a full partnership for the implementation and operation of an assistance hotline with Norton Healthcare. This assistance hotline has served as the Kentucky COVID-19 assistance hotline throughout the current response. KDPH also is making use of this hotline for general information dissemination about the COVID-19 vaccine and to answer various questions from the public that are relevant to the COVID-19 vaccine.

Additionally, KDPH activated a separate “call center” to answer and direct questions from vaccination providers. At the beginning of the COVID-19 response KDPH opened a clinician hotline to field questions about COVID-19 testing and isolation guidance. Based upon the feedback we received from clinicians, the internal KDPH “call center” was well received and is being used again to assist clinicians with any questions or concerns.
SECTION 13: REGULATORY CONSIDERATIONS

Initially, COVID-19 vaccines have been authorized for use under an Emergency Use Authorization (EUA) issued by FDA.

Emergency Use Authorization Fact Sheets

The EUA authority allows FDA to authorize either (a) the use of an unapproved medical product (e.g., drug, vaccine, or diagnostic device) or (b) the unapproved use of an approved medical product during an emergency based on certain criteria. The EUA will outline how the COVID-19 vaccine should be used and any conditions that must be met to use the vaccine. FDA will coordinate with CDC to confirm these “conditions of authorization.” Vaccine conditions of authorization are expected to include distribution requirements, reporting requirements, and safety and monitoring requirements. The EUA will be authorized for a specific time period to meet response needs (i.e., for the duration of the COVID-19 pandemic). Additional information on EUAs, including guidance and frequently asked questions, is located on the FDA website.

Product-specific EUA fact sheet for COVID-19 vaccination providers will be made available that will include information on the specific vaccine product and instructions for its use. The FDA will develop EUA fact sheets for vaccine recipients. The EUA facts sheets will likely be made available on the FDA website and through the CDC website. KDPH will use multiple communication mediums to reach COVID-19 vaccine providers such as email distribution lists, webpages, and ReadyOp alerts to contact enrolled providers and make them aware of the appropriate EUA fact sheets. Furthermore, KDPH will host conference calls and provide training webinars on the EUA fact sheets and the VISs to ensure that providers understand the information, and are clear on the requirement to provide the recipient fact sheet to each client/patient prior to administering vaccine.

Vaccine Information Statements (VIS)

VISs are required only if a vaccine is added to the Vaccine Injury Table. Optional VISs may be produced, but only after a vaccine has been licensed (e.g., such as with zoster vaccines). Plans for developing a VIS for COVID-19 vaccine are not known at this time but will be communicated as additional information becomes available. KDPH will disseminate VISs similarly to how the EUA facts will be disseminated.

Modified Scope of Practice

Kentucky expanded scopes of practice through emergency declaration and executive order. Scopes of practice set forth the range of services that licensed health care practitioners are authorized to perform. A health care professional can only provide services they are deemed eligible to perform by the terms of his/her professional license. Authority to dispense vaccines turns, at least in part, on state law, and is accomplished through several different mechanisms. While legal considerations may vary according to dispensing modality and the type of professional authorized to administer a vaccine, KDPH can adjust vaccine dispensing through legislation, regulatory changes (e.g., health professional boards), standing orders, and emergency orders.
**Administration Fees**

While partner agencies or organizations that provide the COVID-19 vaccine cannot charge clients for the vaccine that they receive from federal and state caches, private partners, such as commercial pharmacies or hospitals, will likely charge an administration fee. This fee offers a financial incentive to provide the vaccine, and covers costs associated with storage and the health care providers’ time, however, it also imposes another barrier to vaccination. Though the administration fees are likely to be capped by federal officials, any fee will frustrate uninsured Kentuckians and reduce vaccination rates among some of the same people most likely to be exposed to infection. KDPH is currently considering a limit on administration fees and will work with providers to ensure the COVID-19 vaccine is accessible and affordable.

To reach uninsured individuals, federal support and funding should be provided for mass vaccination clinics and for reimbursement for providers serving uninsured individuals directly. In all cases, a billing code of some kind will be needed to monitor uptake. KDPH will work to keep barriers to provider participation in administration of the vaccine as low as possible, especially for those providers who are in communities that are disproportionately impacted by COVID-19 by assuring vaccines are available at no cost and that administration of the vaccine is adequately reimbursed even if there is no cost sharing for the patient.

Medicare payment rates for COVID-19 vaccine administration will be $28.39 to administer single-dose vaccines. For a COVID-19 vaccine requiring a series of 2 or more doses, the initial dose(s) administration payment rate will be $16.94, and $28.39 for the administration of the final dose in the series. These rates recognize the costs involved in administering the vaccine, including the additional resources involved with required public health reporting, conducting important outreach and patient education, and spending additional time with patients answering any questions they may have about the vaccine. These rates will also be geographically adjusted.

All organizations and providers participating in the CDC COVID-19 Vaccination Program:

- Must administer COVID-19 Vaccine regardless of the vaccine recipient’s ability to pay COVID-19 Vaccine administration fees or coverage status
- May seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the vaccine recipient
- May not seek any reimbursement, including through balance billing, from the vaccine recipient

**References:**

- [CMS COVID-19 Vaccination Provider Billing](#)
- [CMS COVID-19 Vaccine Policies and Guidance](#)
- [Coverage and Reimbursement of COVID-19 Vaccines, Vaccine Administration and Cost Sharing under Medicaid, the Children’s Health Insurance Program, and Basic Health Program](#)
- [Fourth COVID-19 Interim Final Rule with Comment Period (IFC-4)](#)
- [COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing](#)
SECTION 14: VACCINE SAFETY AND MONITORING

The reporting of adverse events provides the government and the manufacturers with reliable and critical information that is used to evaluate the actual safety and efficacy of the vaccines used in the field. Reporting allows the government and manufacturers to monitor for emerging trends in events and then investigate whether or not the events can be attributed to the vaccine or product. Health care providers and clients benefit from communicated updates of such clinically relevant information. These reports allow the ability to take appropriate actions such as a vaccine recall or a product label change.

In response to vaccine safety, the KDPH Immunizations Branch is utilizing the Vaccine Adverse Event Reporting System (VAERS) to report and investigate adverse events following immunization with the COVID-19 vaccine. VAERS reports should go directly to the VAERS site. KDPH will provide technical assistance and communicate with the CDC on all aspects of vaccine adverse event reporting. Vaccine safety and education will be provided by the CDC and the KDPH Immunizations Branch to providers statewide. It should be emphasized that reports of adverse events from manufacturers or health care practitioners are for the most part only suspected associations.

- Vaccine recipients will be passively monitored for adverse reactions to the vaccine. They will receive instruction on identifying and seeking care for adverse reactions.
- Vaccinators will be responsible for the examination and care of persons with adverse events that occur immediately after vaccination (such as anaphylactic reactions).
- KDPH will provide guidance and recommendations established by the CDC Advisory Committee on Immunization Practices (ACIP) regarding vaccine administration that will include the appropriate immunization schedule, dosage and contraindications. See “Section 4: Critical Populations” for further information.
- KDPH will identify information that must be captured to provide appropriate follow-up of primary vaccines, including adverse reactions. KDPH will educate medical care providers and LHDs regarding adverse reactions and reporting requirements. LHDs will educate patients about reporting adverse events. Adverse events that occur at the vaccinating clinics will be treated and reported at the time of vaccination.
- Medical care providers and Pharmacies will report to VAERS vaccine adverse reactions. LHDs will provide follow up in consultation with KDPH and with support from KDPH as needed. KDPH will report adverse reactions and investigation findings to CDC.

References:
- Vaccine Adverse Event Reporting System (VAERS): http://vaers.hhs.gov/
- VAERS Frequently Asked Questions: https://vaers.hhs.gov/faq.html
SECTION 15: VACCINATION PROGRAM MONITORING

Continuous monitoring for situational awareness throughout the COVID-19 Vaccination Program is crucial for a successful outcome. KDPH has established procedures for monitoring various critical program planning and implementation elements, including performance targets, resources, staffing, and activities.

COVID-19 Vaccination Program Monitoring

The majority of the aforementioned elements are regularly monitored through normal day-to-day operations and under the current COVID-19 State Health Operations Center (SHOC) Incident Command System (ICS). KDPH has hired additional personnel throughout the COVID-19 response and has hired and trained additional personnel in order to handle the expected expansion of services when a vaccine becomes available. Additional staffing and resource needs will be handled utilizing the SHOC ICS reporting structure. The SHOC will work in coordination with the Immunizations Branch to monitor and assess the various information requirements, such as inventory of vaccine, PPE usage, etc. This is discussed further in "Section 2 COVID-19 Organizational Structure and Partner Involvement."

Dashboards

The KDPH Vaccination Planning Team will continue to assess the need for having various information systems and dashboards to monitor and display COVID-19 Vaccination Program information. However, to provide situational awareness for jurisdictions and the general public throughout the COVID-19 vaccination response, the CDC will have two dashboards available.

The Weekly Flu Vaccination Dashboard will include weekly estimates of influenza vaccination for adults, children, and pregnant women (when approved for these groups) using existing (National Immunization Survey [NIS]-Flu) and new (IQVIA) data sources. Data and estimates from additional sources will be added, as available.

The COVID-19 Vaccination Response Dashboard will include:

- Data for planning (e.g., estimates of critical population categories, number and attributes of healthcare providers and facilities)
- Implementation data (e.g., number of enrolled COVID-19 vaccination providers, COVID-19 vaccine supply and distribution, COVID-19 vaccine administration locations)
- COVID-19 vaccine administration data

An additional OWS information system is the Tiberius Platform. Tiberius provides a COVID-19 vaccine distribution planning, tracking, modeling, and analysis ecosystem to support the OWS mission. Leveraging the same technologies as the HHS Protect Platform. Tiberius integrates data sources from Federal agencies, State and Local partners, private sector partners, and open data providers to create a comprehensive Common Operating Picture (“COP”) for the COVID-19 vaccine planning, distribution, and administration effort. Tiberius provides flexible and real time data-backed applications that enable users of all types to make data-driven decisions. KDPH will review the Tiberius Platform and integrate into vaccination operations if it is beneficial and applicable to KDPH information systems.

The COVID-19 Vaccination Response Dashboard will be implemented in stages based on data availability and shareability. Both dashboards will include a “secure” view tailored for jurisdictions (via SAMs Account), and a view for the general public on the CDC’s website.
ORGANIZATION AND ASSIGNMENT OF RESPONSIBILITIES

The following Primary Agencies will continue to coordinate operations with supporting agencies during and after the COVID-19 vaccination campaign. KDPH will continue to serve as the Primary Coordinating Agency during the COVID-19 vaccination campaign. Adjunct responsibilities and tasks may be added during planning and operations to cover situations that arise or that are not addressed in this plan and/or listed below.

Primary Agency – Kentucky Department for Public Health (KDPH)

1. KDPH-Division of Public Health Safety and Protection- Preparedness Branch
   a. Serves as the lead agency for ESF #8 – Public Health and Medical Services and will activate the SHOC to support public health and medical-related operations.
   b. Maintains vehicles, trailers, Personal Protective Equipment(PPE), equipment, and supplies needed for the distribution of vaccine and vaccine supplies;
   c. Coordinates with response partners, bordering states, and the federal government throughout the event;
   d. Provides regular updates and new information as available to all stakeholders, including the community;
   e. Activate and direct the management of a call center focused on providing health information
      Coordinates with the Office of Communications to use media relations and outreach plan
      disseminate risk communication messages;
   f. Provides operational support for vaccine response activities determined to be appropriate by the
      Division of Epidemiology and Health Planning.

2. KDPH-Division of Epidemiology and Health Planning- Infectious Disease Branch
   a. Reviews surveillance data to aid prioritization decisions for vaccines and antivirals;
   b. Provides epidemiological support to LHDs, hospitals, and other healthcare agencies
   c. Recommends use of control measures including non-pharmaceutical interventions, vaccine, and
      antivirals in accordance with CDC guidelines;

3. KDPH-Division of Epidemiology and Health Planning- Immunizations Branch
   a. Oversees the procurement of the vaccine (if necessary) as it is made available by the manufacturers over several months, for distribution through multiple phases as the situation unfolds.
   b. Coordinates the distribution of the vaccine through established systems for the vendors to
      transport to the appropriate community services providers (i.e., hospitals, health care providers,
      or local health departments) in accordance with the CDC guidance to facilitate access for the
      specified Target groups.
c. Assembles fact sheets for health care professionals about the novel virus, diagnosis and treatment;
d. Develops and/or provides guidance on delivery protocols and procedures;
e. Coordinates with partner organizations to implement systems to identify target populations, and estimate amount of antiviral medications and vaccine they will need;
f. Ascertains from CDC and manufacturers the availability of vaccine and antivirals;
g. Implements plans for delivery, storage, and administration of vaccine as it becomes available (update plans as necessary in coordination with the Public Health Preparedness Branch);
h. Monitors vaccine, antiviral, and other supplies using the Mass Event module of the Kentucky Immunization Registry or other system as needed;
i. Ensures that all identified vaccinators are authorized, identified, and have access to the Kentucky Immunization Registry;
j. Leads the state response to vaccine shortage related issues;
k. Packages and distributes educational materials for the public, health professionals, and the media for reporting adverse events for antiviral medications using MedWatch and for vaccine using the Vaccine Adverse Event Reporting System (VAERS);
l. Reviews data from MedWatch and VAERS reports;
m. Notifies LHDs, Infection Control Professionals, physicians, hospitals, and health systems, the media, and all other relevant health care professionals and associations including those responsible for special populations of the vaccine campaign and associated operations.

Support Agencies
The following Support Agencies have a major role during the COVID-19 vaccination campaign as outlined within this plan. Other local, state, or federal agencies may provide logistical and technical support per the Kentucky EOP and supporting ESF Annexes. Adjunct responsibilities and tasks may be added during planning and operations to cover situations that arise or that are not addressed in this plan and/or listed below.

1. Cabinet for Health and Family Services (CHFS) - Office of Communications
   a. Coordinates the communications response and media relations for ESF #8 through coordination with CHFS, KDPH, and ESF #8 agencies;
   b. Serves in the Public Information role for ESF #8 from a virtual setting or at the state’s JIC, KDPH’s SHOC, or in field settings;
   c. Provides support to local and state agencies in the development and release of public information.

2. Kentucky Emergency Management (KYEM)
   a. Supports ESF #8 in coordinating public health and medical preparedness, response and recovery activities with other ESFs and local, state, and federal agencies;
b. Provides support to local and state agencies for developing and releasing emergency public information and warnings through ESF #15 – Public Information and/or activation of a Joint Information Center (JIC);

c. Provides administrative support to recovery efforts by assisting in the processing of documents authorizing payments to local governments, and state agencies.

3. Kentucky Pharmacists Association (KPhA)
   a. Supports public health and medical response efforts as a liaison between ESF #8 – Public Health and Medical Services and pharmaceutical partners;
   b. Work with healthcare partners and other stakeholders to distribute, deliver, and administer pandemic vaccines to priority groups;
   c. Disseminates information to statewide pharmaceutical providers;
   d. Collaborates with public health agencies to distribute vaccine;
   e. Keeps KDPh updated on the available inventory and shortages of pharmaceuticals;
   f. Identifies volunteer pharmacists to assist with administration of vaccine;
   g. Considers development of vendor agreements to streamline acquisition and distribution of vaccine.

4. Kentucky Hospital Association (KHA)
   a. Supports public health and medical response efforts as a liaison between ESF #8 – Public Health and Medical Services, hospitals, HCCs, and other community healthcare partners;
   b. Disseminates information to statewide healthcare providers;
   c. Assists in the distribution of practitioner-level information related to medical countermeasures through appropriate distribution channels;
   d. Assesses supply chain, staffing, and other impacts on medical care facilities and ascertains whether medical resources are sufficient;
   e. Assists with the collection and interpretation of hospital reporting data;
   f. Assists with the deployment of prepositioned medical response assets including but not limited to pharmaceuticals, antiviral medications.

5. Kentucky National Guard (KYNG)
   a. Provides available personnel and equipment to support the receipt and distribution of state and federal assets;
   b. Coordinates the activation and deployment of appropriate response personnel and other assets to provide immediate response capabilities including command and control, logistical support and transportation;

6. Kentucky State Police (KSP)
a. When necessary, provides support to KDPH and local law enforcement agencies when vaccine is being transported, distributed or dispensed;
b. Assists local law enforcement with any requested tasks such as law and order, and crowd control;
c. Coordinates with the local law enforcement agencies for security and traffic control during operations involving the movement and dispensing of resources such as vaccines.

7. Kentucky Board of Emergency Medical Services (KBEMS):
   a. Works with KDPH to organize and vaccinate emergency medical services (EMS) agencies;
   b. If necessary, works with KDPH to modify scope of practice for EMTs and Paramedics to carry out vaccinations

8. Kentucky Transportation Cabinet (KYTC)
   a. Serve as the lead agency for ESF #1 - Transportation;
   b. Coordinate the state’s transportation resources for the routing and logistical movement of personnel, equipment, and supplies;
   c. Supports the storage, transportation and distribution of the vaccine through established systems to transport to the appropriate community services providers (i.e., hospitals, health care providers, or local health departments).

Local Agencies
Generalized coordination responsibilities and actions for elements of local government are outlined below. Other local, state, or federal agencies provide support as applicable.

1. Local Health Department/District
   a. In coordination with KDPH, coordinate the planning for and the implementation of COVID-19 vaccination operations;
   b. Maintain specific strategies, plans, and protocols for administering vaccine pursuant to the State’s guidelines;
   c. Work with healthcare partners and other stakeholders to distribute, deliver, and administer pandemic vaccines to priority groups;
   d. Work with large business and schools regarding plans for vaccination;
   e. Identify vaccination clinic sites (number, locations, points of contact, alternative sites, accessibility)
   f. Conduct training for public health staff and partners involved in distributing and administering vaccines;
   g. Monitor vaccine supplies, distribution, and use;
   h. Monitor and report adverse events;
i. Coordinate the operation of Points of Dispensing (PODs) for mass vaccination;

j. Provide effective communications to staff, community partners, news media, and the public;

k. Coordinate with healthcare coalition and support the information and resource needs of healthcare facilities

2. **Community Hospitals**
   a. Work with LHD and other stakeholders to administer vaccine to priority groups;
   b. Allocate, secure, and monitor the use of the vaccine distributed to the hospital, as vaccine is made available;
   c. Maintain specific strategies, plans, and protocols for administering vaccine pursuant to the State’s guidelines;
   d. Administer vaccine to priority groups among staff pursuant to the State’s guidelines
   e. Monitor vaccine supplies, distribution, and use;
   f. Monitor and report adverse events;
   g. Coordinate with the LHD and support the information and resource needs of the LHD.

3. **County Emergency Management Agencies**
   a. Supports the LHD in coordinating COVID-19 vaccination preparedness and response activities;
   b. Coordinates the activation and deployment of appropriate response personnel and other assets to support vaccination operations;
   c. Coordinate with LHD to receive and act on requests for assistance;
   d. Maintain communications with local government officials and KYEM.

4. **Local EMS Agencies**
   a. If applicable, coordinate with the LHD, healthcare facilities and other applicable agencies to support vaccination operations.

5. **Local Law Enforcement Agencies**
   a. When necessary, provides support to the LHD when vaccine is being transported, distributed or dispensed;
   b. Assists with any requested tasks such as law and order, and crowd control;
   c. Coordinate security and traffic control during operations involving the movement and dispensing of resources such as vaccines.
   d. Coordinate and assist KSP.
AUTHORITIES AND REFERENCES

Legal Authorities

Federal
- Robert T. Stafford Act Disaster Relief and Emergency Assistance Act Section 319 of the Public Health Service Act – Declaration of a Public Health Emergency;

State
- Kentucky Revised Statutes (KRS), Title XVIII - Public Health;
- KRS 398.045 - Mutual aid agreements between Kentucky or its agencies or political subdivisions and units of government from another state;
- KRS 311A.170 – Paramedics – Permitted activities – Employment by hospitals – Reasonable control by employers;
- KRS 311A.175 – Exceeding scope of practice – Discipline prohibited for refusal to exceed scope of practice;
- KRS 315.500 - Emergency authority for pharmacists during state of emergency;
- KRS 411.148 - Non-liability of licensees and certified technicians for emergency care;
- 106 KAR 5:040 - Initiation of a crisis or disaster response;
- 202 KAR 7:701 - Scope of Practice Matters - Exemptions;
- 902 KAR 2:055. Immunization data reporting and exchange
- 214.015 Reporting of authorized or required immunization

References

Federal
- CISA Guidance on Essential Critical Infrastructure Workers Version 4.0 (2020)
- CDC’s established General Principles and Interim Guidance on Pandemic Vaccination (2018)

State
- Modeling Pandemic Influenza Vaccination Capacity for Adults-Kentucky Report (2016)
- Kentucky Immunization Providers Manual (2020)
- Cabinet for Health and Family Services’ Emergency Communication Plan;
- Kentucky Department for Public Health’s Disease Outbreak Support Plan;
- Kentucky Department for Public Health’s State Health Operations Center Support Plan;
- Kentucky Emergency Operations Plan;
- Kentucky Medical Countermeasures Plan;

Other
- Johns Hopkins University’s Center for Health Security- Interim Framework for COVID-19 Vaccine Allocation and Distribution in the United States
ATTACHMENT 1: VACCINATION RESOURCES AND CHECKLISTS

In an effort to standardize the process of holding clinics in non-traditional settings, the National Adult and Influenza Immunization Summit developed tools your organization can use when organizing satellite, temporary, or off-site vaccination clinics. You can access these resources at izsummitpartners.org under Tools to Assist Satellite, Temporary, and Off-Site Vaccination Clinics or use the direct links to the vaccination clinic resources below:

Best Practices Checklist
This checklist is a step-by-step guide to help clinic coordinators/supervisors overseeing vaccination clinics held at satellite, temporary, or off-site locations follow Centers for Disease Control and Prevention (CDC) guidelines and best practices for vaccine shipment, transport, storage, handling, preparation, administration, and documentation. This checklist outlines CDC guidelines and best practices that are essential for patient safety and vaccine effectiveness.
- Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-site Locations

Vaccination Clinics Organization Pledge
This annual pledge is for organizations that conduct satellite, temporary, or off-site vaccination clinics to affirm that they will adhere to best practices, including using the Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations. Organizations that sign the pledge will be recognized on the Summit website for their commitment to provide safe and effective vaccine clinics. Companies seeking to hire an organization to conduct a vaccination clinic can check to see if that organization has signed the pledge and is recognized on the Summit website.
- Pledge for Organizations Implementing Vaccination Clinics Held at Satellite, Temporary, or Off-site Locations

Ten Principles for Holding a Safe Vaccination Clinic
This resource, which supplements the checklist, serves as a quick reference guide highlighting the main points of the checklist that can be used by all staff (not just the clinic coordinators/supervisors who are completing the checklist). This document can be posted on the wall of the clinic or given out to all the staff who are vaccinating at the clinic.
- Ten Principles for Holding Safe Vaccination Clinics at Satellite, Temporary, or Off-site Locations

Frequently Asked Questions about the Best Practices for Vaccination Clinics
This list of Frequently Asked Questions provides answers to some of the most common questions about the purpose of the checklist and pledge, the intended users of the checklist, how to use the checklist, and technical questions.
- Frequently Asked Questions about the Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-site Locations and Pledge for Implementing the Checklist

Other Resources:
Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

Skills Checklist for Vaccine Administration
Checklist for Safe Vaccine Storage and Handling
http://www.immunize.org/catg.d/p3035.pdf

CDC Vaccine Storage and Handling (link to CDC’s Vaccine Storage and Handling Toolkit may be found from this site)
https://www.cdc.gov/vaccines/hcp/admin/storage-handling.html

CDC Vaccine Admin
https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html

Provider's Role: Importance of Vaccine Administration and Vaccine Storage & Handling
https://www.cdc.gov/vaccines/hcp/admin/storage/providers-role-vacc-admin-storage.html

IAC Vaccine Storage and Handling
http://www.immunize.org/handouts/vaccine-storage-handling.asp

IAC Vaccine Admin
http://www.immunize.org/handouts/administering-vaccines.asp

Vaccine Storage and Handling Video (50 mins with CE credit available)
https://www2.cdc.gov/vaccines/ed/shvideo/shvideo.asp

You Call the Shots (CDC web-based training course on many vaccines with CE credit available)
https://www.cdc.gov/vaccines/ed/youcalltheshots.html

Critical Infrastructure Employees:
### ATTACHMENT 2: OVERVIEW OF ALLOCATION FRAMEWORKS

**Overview of Allocation Frameworks Developed for Vaccine Allocation during the COVID-19 Pandemic**

<table>
<thead>
<tr>
<th>Effort</th>
<th>Leaders</th>
<th>Goals</th>
<th>Guiding Principles</th>
<th>Prioritized Groups</th>
</tr>
</thead>
</table>
  o Promote public health  
  o Promote economic and social well-being  
• Treat people fairly and equally  
  o Address background and emerging inequities between groups  
  o Give priority to worst-off individuals  
  o Reciprocity  
• Promote legitimacy, trust, and a sense of ownership in a pluralistic society  
  o Respect the diversity of views in a pluralistic society  
  o Engage community members to improve vaccine program design and effectiveness | Tier 1:  
• Those most essential in sustaining the ongoing COVID-19 response  
• Those at greatest risk of severe illness and death, and their caregivers  
• Those most essential to maintaining core societal functions  

Tier 2:  
• Those involved in broader health provision  
• Those who face greater barriers to access care if they become seriously ill  
• Those contributing to maintenance of core societal functions  
• Those whose living or working conditions give them an elevated risk of infection, even if they have lesser or unknown risk of severe illness and death |
| ACIP COVID-19 Vaccine Workgroup | ACIP | • Develop a plan for allocation of vaccine in the United States. | • Maximize benefits and minimize harms  
  • Equity  
  • Justice  
  • Fairness  
  • Transparency | In progress at the time of this writing |
ATTACHMENT 3: FRAMEWORK FOR EQUITABLE ALLOCATION OF COVID-19 VACCINE


Applying the Allocation Criteria to Specific Population Groups (Sub-prioritization)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>High-risk health workers</td>
<td>H</td>
<td>M</td>
<td>H</td>
<td>H</td>
<td>Adequate access to personal protective equipment. Workplace management of exposure.</td>
</tr>
<tr>
<td>1a</td>
<td>First responders</td>
<td>H</td>
<td>M</td>
<td>H</td>
<td>H</td>
<td>Adequate access to personal protective equipment. Workplace management of exposure.</td>
</tr>
<tr>
<td>1b</td>
<td>People with significant comorbid conditions (defined as having two or more)</td>
<td>M</td>
<td>H</td>
<td>M</td>
<td>M</td>
<td>Ability to maintain social distance and isolate.</td>
</tr>
<tr>
<td>1b</td>
<td>Older adults in congregate or overcrowded settings</td>
<td>H</td>
<td>H</td>
<td>L</td>
<td>M</td>
<td>Effective institutional management of exposure.</td>
</tr>
<tr>
<td>2</td>
<td>K–12 teachers and school staff and child care workers</td>
<td>H</td>
<td>M</td>
<td>H</td>
<td>H</td>
<td>Online schooling, especially for lower grades, recognizing educational and social impacts.</td>
</tr>
<tr>
<td>2</td>
<td>Critical workers in high-risk settings</td>
<td>H</td>
<td>M</td>
<td>H</td>
<td>M</td>
<td>Adequate access to personal protective equipment. Workplace management of exposure.</td>
</tr>
<tr>
<td>2</td>
<td>People with moderate comorbid conditions</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>Ability to maintain social distance and isolate.</td>
</tr>
<tr>
<td>Phase</td>
<td>Population Group</td>
<td>H Risk</td>
<td>M Risk</td>
<td>L Risk</td>
<td>H Risk</td>
<td>Notes</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2</td>
<td>People in homeless shelters or group homes and staff</td>
<td>H</td>
<td>H</td>
<td>L</td>
<td>H</td>
<td>Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.</td>
</tr>
<tr>
<td>2</td>
<td>Incarcerated/detained people and staff</td>
<td>H</td>
<td>M</td>
<td>L</td>
<td>H</td>
<td>Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.</td>
</tr>
<tr>
<td>2</td>
<td>All older adults</td>
<td>M</td>
<td>H</td>
<td>L</td>
<td>L</td>
<td>Ability to maintain social distance and isolate.</td>
</tr>
<tr>
<td>3</td>
<td>Young adults</td>
<td>H</td>
<td>L</td>
<td>M</td>
<td>H</td>
<td>Ability to maintain social distance and isolate. Closure of congregate settings (e.g., bars).</td>
</tr>
<tr>
<td>3</td>
<td>Children</td>
<td>M</td>
<td>L</td>
<td>M</td>
<td>H</td>
<td>Ability to participate in online schooling.</td>
</tr>
<tr>
<td>3</td>
<td>Workers in industries important to the functioning of society</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>Adequate access to personal protective equipment. Effective institutional/workplace management of exposure.</td>
</tr>
</tbody>
</table>


NOTES: Cell entries are for a typical member of each group. H = high risk; L = low risk; M = medium risk. All groups are heterogeneous, and ratings indicate the median risk. All cell entries are relative to risks in the overall population, not measures of absolute risk, and are based on the committee’s expert judgment of the evidence and the unknowns at the time of the report’s writing. There is no weighting of these different criteria and no aggregation. Within each phase, the population groups are of similar priority, and authorities have the flexibility to adapt the priority population groups to their specific conditions. Lastly, the committee has elected not to use the designation “essential worker.” Instead, the committee refer to these workers as critical workers in high-risk settings as they are both working in industries vital to the functioning of society and in occupations where they cannot avoid exposure risk by, for example, teleworking. This is described in additional detail later in this chapter.
**ATTACHMENT 4: PROJECTED VACCINATION TARGET GROUPS**

On October 2, the National Academies of Sciences, Engineering, and Medicine’s Committee on Equitable Allocation of Vaccine for the Novel Coronavirus released the *“The National Academies’ Framework for Equitable Allocation of COVID-19 Vaccine”* (2020), in which it outlines a preliminary framework for equitable allocation of COVID-19 vaccine. By looking at the various guidance documents, KDPH can speculate about who the phased targeted/target groups may be for the COVID-19 vaccine. Possible COVID-19 phased target groups are reflected in the table below. It is important to emphasize that we are not providing a set of definitive recommendations about who should be prioritized for vaccination. Rather, we have identified candidate groups that will be given serious consideration as priority groups. Ultimately, KDPH and the Vaccine Allocation Committee will use new guidance in conjunction with previous published guidance to ultimately determine who the target populations and target groups are.

<table>
<thead>
<tr>
<th>Category</th>
<th>Targeted Group/Priority Group</th>
<th>Rationale</th>
<th>Est Pop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Care</td>
<td>Front-line inpatient and hospital-based health care workers</td>
<td>Critical role in providing care for the sickest persons; highest risk of exposure and occupational infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Health Care</td>
<td>Long Term Care and Assisted Living Facilities workers</td>
<td>Critical role in providing care for the highest risk population; close contact with people at very high risk of poor outcomes</td>
<td>In Progress</td>
</tr>
<tr>
<td><em>Medically Vulnerable Population</em></td>
<td>Vulnerable congregates care setting residents</td>
<td>People at greatest risk of becoming infected and seriously ill</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Front-line Emergency Medical Service personnel <em>(those providing patient assessment, triage, and transport).</em></td>
<td>Provide critical medical care including procedures such as intubation that increase risk of aerosol exposure and occupational infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Front-line Fire and Law Enforcement personnel</td>
<td>Essential to public order and safety;</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Pharmacists and Pharmacy Technicians</td>
<td>Critical role in provision of health services; working conditions give them elevated risk of infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Manufacturers of Pandemic Vaccines &amp; Antivirals</td>
<td>Critical role in provision of health services; working conditions give them elevated risk of infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Phase 1B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Care</td>
<td>Outpatient health services focused on serving high risk groups <em>(oncology clinics, dialysis clinics)</em></td>
<td>Critical role in providing care for the highest risk population; close contact with people at very high risk of poor outcomes</td>
<td>In Progress</td>
</tr>
<tr>
<td><strong>Health Care</strong></td>
<td>Front-line outpatient health care providers</td>
<td>Effective outpatient care is critical to decrease the burden on hospitals; high risk of exposure and occupational infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>High risk National Guard personnel</td>
<td>Essential to public order and safety</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Frontline medical device repair and maintenance workers</td>
<td>Critical role in provision of health services; working conditions give them elevated risk of infection</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Corrections Facilities workers</td>
<td>Essential to public order and safety; Working conditions give them elevated risk of infection; close contact with people at very high risk of poor outcomes</td>
<td>In Progress</td>
</tr>
<tr>
<td><em>Vulnerable Population</em></td>
<td>Correctional Facility Residents</td>
<td>People who would prevent the risk of spread if vaccinated</td>
<td>In Progress</td>
</tr>
<tr>
<td>Community Support Services</td>
<td>Frontline Social Services workers</td>
<td>Workers carrying out critical, frontline interventions in the community; working conditions give them elevated risk of infection</td>
<td>In Progress</td>
</tr>
<tr>
<td><strong>Health Care</strong></td>
<td>Critical outpatient health services (mental health providers, etc.)</td>
<td>Critical role in provision of health services;</td>
<td>In Progress</td>
</tr>
<tr>
<td>Community Support Services</td>
<td>High Risk Congregate setting workers (community food and housing)</td>
<td>Critical role in provision of health services; working conditions give them elevated risk of infection</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

**Phase 2**

| Critical Infrastructure | Pre K-12 Education personnel | School workers are essential to educating children and enabling many parents to return to work; Working in high-density or high-contact jobs where distancing may not be feasible. | In Progress |
| Critical Infrastructure | Utility and Telecommunications personnel (water and sewer, gas and electric, communication infrastructure) | Protect workers needed to maintain critical infrastructure; Essential to public order and safety; | In Progress |
| Critical Infrastructure | Public Transportation workers | Working in high-density or high-contact jobs where distancing may not be feasible; Worker groups with a high rate of lower-income workers | In Progress |
### Critical Infrastructure

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>In Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Targeted&quot; food manufacturing and processing facility workers</td>
<td>Working in high-density or high-contact jobs where distancing may not be feasible; Worker groups with a high rate of lower-income workers</td>
<td>In Progress</td>
</tr>
<tr>
<td>Retail Food and Grocers, Food Service workers</td>
<td>Working in high-density or high-contact jobs where distancing may not be feasible; Worker groups with a high rate of lower-income workers</td>
<td>In Progress</td>
</tr>
<tr>
<td>Higher Education personnel</td>
<td>Working in high-density or high-contact jobs where the risk of spread is elevated</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Government personnel</td>
<td>Essential to public order and safety;</td>
<td>In Progress</td>
</tr>
<tr>
<td>Transportation delivery drivers and warehouse workers</td>
<td>Protect workers needed to maintain critical infrastructure; Working in high-density or high-contact jobs where distancing may not be feasible; Worker groups with a high rate of lower-income workers</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

### *Vulnerable Population*

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>In Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disadvantaged and vulnerable populations (possibly addressed in Phase 3)</td>
<td>Mitigate the impact of social inequities on COVID-19 outcomes in disadvantaged communities at risk of disproportionate burdens</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

### Phase 3

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>In Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Vulnerable Population</em></td>
<td>Vulnerable general population (age 60+, co-morbid conditions)</td>
<td>In Progress</td>
</tr>
<tr>
<td><em>Vulnerable Population</em></td>
<td>High-risk Children, High-risk nonelderly adults, Pregnant women (subject to change)</td>
<td>In Progress</td>
</tr>
<tr>
<td>Critical Infrastructure</td>
<td>Workers in industries and occupations at an increased risk of exposure not included in previous phases</td>
<td>In Progress</td>
</tr>
</tbody>
</table>

### Phase 4

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>In Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>“General Population”</td>
<td></td>
<td>In Progress</td>
</tr>
</tbody>
</table>
ATTACHMENT 5: VACCINE “A” INFORMATION

Vaccine “A” Storage and Handling Guide
## Vaccine A Vaccination Provider Site Archetypes for Shipment Timing and Site Planning

<table>
<thead>
<tr>
<th>Vaccination provider site</th>
<th>Order size</th>
<th>Storage conditions</th>
<th>Patient flow</th>
<th>Number of immunizers</th>
<th>Patients per immunizer</th>
<th>Hours per day</th>
<th>Vaccines per day</th>
<th>Shipment model</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A – large outpatient center (mass vx)</strong></td>
<td>1 tray (975 doses)</td>
<td>Thermal box with dry ice, 2-8C fridge, for product estimated at site (5 days)</td>
<td>~500/day</td>
<td>10 immunizers</td>
<td>6 patients/hour (~10 min/Vx)</td>
<td>8 hours</td>
<td>480 vaccinations</td>
<td>1 tray; 2-3 times per week</td>
</tr>
<tr>
<td><strong>B – hospital or outpatient center</strong></td>
<td>1 tray (975 doses)</td>
<td>Ultra-cold freezer, Thermal box with dry ice, 2-8C fridge, for product estimated at site (5 days)</td>
<td>Variable</td>
<td>4 immunizers</td>
<td>6 patients/hour (~10 min/Vx)</td>
<td>8 hours</td>
<td>192 vaccinations</td>
<td>1 tray; every week</td>
</tr>
<tr>
<td><strong>C – large hospital with affiliated outpatient center</strong></td>
<td>5 trays (4,875 doses)</td>
<td>Ultra-cold freezer, Thermal box with dry ice, 2-8C fridge, for product estimated at site (5 days)</td>
<td>Variable</td>
<td>7 immunizers</td>
<td>6 patients/hour (~10 min/Vx)</td>
<td>8 hours</td>
<td>340 vaccinations</td>
<td>1 tray; 1-2 times a week</td>
</tr>
<tr>
<td><strong>D – outdoor parking lot vaccination hub at large retail pharmacy</strong></td>
<td>1 tray (975 doses)</td>
<td>2-8C fridge, for product estimated at site (5 days)</td>
<td>~200/day</td>
<td>5 immunizers</td>
<td>6 patients/hour (~10 min/Vx)</td>
<td>N/A</td>
<td>240 vaccinations</td>
<td>1 tray; every week</td>
</tr>
<tr>
<td><strong>E – mobile vaccination in targeted geographic areas</strong></td>
<td>5 trays (4,875 doses)</td>
<td>2-8C fridge, for product estimated in mobile unit (8 days)</td>
<td>Variable</td>
<td>3 immunizers</td>
<td>6 patients/hour (~10 min/Vx)</td>
<td>Not specified</td>
<td>150 vaccinations</td>
<td>1 tray; every week</td>
</tr>
</tbody>
</table>
## Site Types for Vaccine A Product

<table>
<thead>
<tr>
<th>Vaccination provider site</th>
<th>Order size</th>
<th>Storage conditions</th>
<th>Patient flow</th>
<th>Number of immunizers</th>
<th>Patients per HCP</th>
<th>Hours per day</th>
<th>Vaccines per day</th>
<th>Shipment model</th>
</tr>
</thead>
<tbody>
<tr>
<td>F – large indoor spaces</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>not used during pandemic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(convention hall)</td>
<td>5 trays (4,875 doses)</td>
<td>Thermal box with dry ice, 2-8°C fridge, for product estimated at site (5 days)</td>
<td>Variable</td>
<td>10 immunizers</td>
<td>6 patients/hour (~10 min/’X’)</td>
<td>8 hours</td>
<td>480 vaccinations</td>
<td>2-3 trays; every week</td>
</tr>
<tr>
<td>G – Drive-through</td>
<td>3 trays (2,925 doses)</td>
<td>Thermal box with dry ice, 2-8°C fridge, for product estimated at site (5 days)</td>
<td>Variable</td>
<td>10 immunizers</td>
<td>6 patients/hour (~10 min/’X’)</td>
<td>8 hours</td>
<td>480 vaccinations (by 7 days)</td>
<td>2-3 trays; very week</td>
</tr>
</tbody>
</table>
ATTACHMENT 6: VACCINE “B” INFORMATION

Vaccine “B” Storage and Handling Guide

Vaccine B

Vaccine Storage

Vaccine Thawing

Vaccine Packaging

10 doses per vial (10 doses)
10 vials per carton (100 doses)
12 cartons per case (1200 doses)

Freezer

Refrigeration

2 hour thaw

Room temperature

15 minute warm

Unopened vial may be stored at room temperature for 12 hours.

Once vial is punctured, remaining doses must be discarded after 6 hours.

6 Hours
ATTACHMENT 7: KENTUCKY’S INTERIM RECOMMENDATION FOR ALLOCATING SUPPLIES OF COVID-19 VACCINE (1-4-20)

* Phases are subject to change and are listed for planning purposes only

<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 A</td>
<td>Long term care facilities, assisted living facilities, health care personnel</td>
</tr>
<tr>
<td>1 B</td>
<td>First responders, anyone age 70 or older, Kentucky K-12 school personnel</td>
</tr>
<tr>
<td>1 C</td>
<td>Anyone age 60 or older, anyone age 16 or older with CDC highest risk COVID-19 risk conditions, all essential workers</td>
</tr>
<tr>
<td>2</td>
<td>Anyone age 40 or older.</td>
</tr>
<tr>
<td>3</td>
<td>Anyone age 16 or older.</td>
</tr>
<tr>
<td>4</td>
<td>Children under the age of 16 if the vaccine is approved for this age group (est. 18% of KY population)</td>
</tr>
</tbody>
</table>

References:
- Vaccine Recommendations and Guidelines of the ACIP
- Interim Considerations for Phased Implementation of COVID-19 Vaccination and Sub-Prioritization Among Recommended Populations

https://chfs.ky.gov/agencies/dph/covid19/20210104_Phasesbupdate.pdf